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ABSTRACT
Cardiovascular complications are the major cause of morbidity and mortality in diabetic
patients. Accelerated atherogenesis and related vascular diseases increase the need for
revascularization procedures and for the development of improved therapeutical
approaches. Proangiogenic gene therapy represents a promising treatment option for
myocardial and limb ischemia. However, enhanced neovascularization can also contribute
to certain pathogenic processes, such as atherosclerotic lesion progression and the
development of diabetic retinopathy. Although clinical trials of therapeutic angiogenesis
have shown a favourable safety profile, concerns have been raised based on animal studies.
The aim of this thesis was to assess the safety and effects of vascular endothelial growth
factor (VEGF) gene therapy with respect to atherosclerosis, and to develop better
experimental models for use in preclinical research by establishing and characterizing a new
mouse model replicating type 2 diabetes and its associated vascular complications.
In contrast to previous mouse studies, no evidence of increased atherosclerosis was found
following systemic adenoviral gene transfers of different VEGFs in hypercholesterolemic
LDLR–/–ApoB100/100 mice. In order to establish a mouse model simulating diabetic vascular
complications, LDLR–/–ApoB100/100 mice  were  cross-bred  with  mice  in  which  type  2  diabetes
develops as a consequence to overexpression of insulin-like growth factor-II (IGF-II) in
pancreatic beta cells. The resulting IGF-II/LDLR–/–ApoB100/100 model demonstrated typical
type 2 diabetic metabolic characteristics as well as a worsening of the atherosclerotic lesion
phenotype. Both the LDLR–/–ApoB100/100 and diabetic IGFII/LDLR–/–ApoB100/100 mice displayed
extensive coronary artery disease leading to left ventricular dysfunction with structural and
functional evidence suggestive of chronic myocardial hibernation. IGFII/LDLR–/–ApoB100/100
mice also exhibited altered retinal morphology and photoreceptor atrophy, but there were
no microvascular changes typical of diabetic retinopathy.
In conclusion, adenovirus-mediated gene transfers of VEGFs had no proatherogenic
effects in hypercholesterolemic mice. This supports the clinical trial data, and indicates that
the testing and development of VEGF gene therapy for cardiovascular diseases can proceed
without unnecessary concerns about accelerated atherogenesis. Furthermore, a promising
new model of macrovascular complications in type 2 diabetes was developed and
characterized, and is now available for experimental and translational research.
National Library of Medicine Classification: WK 810, WK 835, WG 550, QZ 52, QY 58, QY 60.R6, QU 107
Medical Subject Headings: Gene Therapy; Disease Models, Animal; Mice; Atherosclerosis; Vascular
Endothelial Growth Factors/therapeutic use; Diabetes Mellitus, Type 2/complications; Safety; Gene
Transfer Techniques; Adenoviridae; Hypercholesterolemia; Coronary Artery Disease; Ventricular
Dysfunction, Left
VI
VII
Heinonen, Suvi
Diabetekseen liittyvien sydän- ja verisuonikomplikaatioiden mallintaminen - Uuden hiirimallin
kehittäminen ja geeniterapiasovelluksen arviointi
Itä-Suomen yliopisto, terveystieteiden tiedekunta, 2011
Itä-Suomen yliopiston julkaisuja. Terveystieteiden tiedekunnan väitöskirjat 75. 2011. 78 s.
ISBN (print): 978-952-61-0547-5
ISBN (pdf): 978-952-61-0548-2
ISSNL (print): 1798-5706
ISSN (pdf): 1798-5706
ISSN-L: 1798-5714
TIIVISTELMÄ
Tyypin 2 diabetes on kasvava kansanterveysongelma, johon liittyy merkittävä sydän- ja
verisuonisairauksien riski. Kaikilla sydämen tai alaraajojen valtimoiden pallolaajennusta tai
ohitusleikkausta tarvitsevilla potilailla perinteisillä menetelmillä ei saada riittävää
hoitovastetta, tai menetelmiä ei voida soveltaa vaikean taudinkuvan vuoksi. Verisuonten
uudismuodostuksen aikaansaaminen kasvutekijägeeninsiirron avulla (terapeuttinen
angiogeneesi) on osoittautunut lupaavaksi uudeksi hoitomuodoksi sydänlihaksen ja
alaraajojen verenkierron parantamisessa. Kliinisissä kokeissa terapeuttinen angiogeneesi on
osoittautunut turvalliseksi, mutta muutamista eläinkokeista on saatu viitteitä valtimon-
kovettumataudin lisääntymisestä kasvutekijöiden vaikutuksesta. Tämän tutkimuksen
tarkoituksena oli arvioida verisuonen endoteelikasvutekijöiden (VEGF) vaikutusta
valtimonkovettumatautiin, sekä tuottaa prekliiniseen tutkimukseen parempia tautimalleja
kehittämällä ja karakterisoimalla tyypin 2 diabetesta ja siihen liittyviä kardiovaskulaarisia
sairauksia ilmentävä hiirimalli.
Aiemmista hiirillä tehdyistä tutkimuksista poiketen adenovirusvälitteisten VEGF-A, -B,
-C tai -D geeninsiirtojen ei havaittu lisäävän valtimonkovettumatautia hyperkolesterolemi-
sessa LDLR–/–ApoB100/100 hiirimallissa. Mallintaaksemme diabeettisia kardiovaskulaari-
komplikaatioita, LDLR–/–ApoB100/100 hiiret risteytettiin hiirikantaan, jossa tyypin 2 diabetes
aiheutuu insuliininkaltaisen kasvutekijä-II:n (IGFII) yli-ilmentämisestä haiman
beetasoluissa. IGF-II/LDLR–/–ApoB100/100 hiirissä  tyypin 2 diabetes aiheutti ateroskleroottisten
leesioiden pahenemisen. Sekä LDLR–/–ApoB100/100 että IGF-II/LDLR–/–ApoB100/100 hiirille
kehittyi lisäksi vakava sepelvaltimotauti, joka aiheutti sydämen vasemman kammion
toimintahäiriön. IGF-II/LDLR–/–ApoB100/100 hiirillä esiintyi muutoksia myös silmän
verkkokalvon rakenteessa ja fotoreseptorien atrofiaa, mutta diabeettiseen retinopatiaan
viittaavia verisuonimuutoksia ei havaittu.
Yhteenvetona voidaan todeta, että VEGF:n tilapäinen yli-ilmentäminen ei lisännyt
valtimonkovettumatautia hyperkolesterolemisissa LDLR–/–ApoB100/100 hiirissä. Tämä vahvis-
taa kliinisissä kokeissa saatuja tuloksia ja viittaa siihen, että VEGF-geeniterapiasovellusten
tutkimus ja kehitys sydän- ja verisuonitauteihin voi edetä ilman merkittävää huolta
valtimonkovettumataudin kiihtymisestä. Tutkimuksessa kehitetyssä uudessa hiirimallissa
yhdistyvät aikuistyypin diabetekselle tyypilliset metaboliset häiriöt sekä valtimon-
kovettumataudista aiheutuvat sydän- ja verisuonisairaudet, ja mallia voidaan soveltaa
sairauksien syntymekanismien tutkimiseen ja uusien hoitomuotojen kehittämiseen.
Luokitus: WK 810, WK 835, WG 550, QZ 52, QY 58, QY 60.R6, QU 107
Yleinen suomalainen asiasanasto: geeniterapia; eläinkokeet; hiiret; sydän- ja verisuonitaudit; ateroskleroosi;
diabetes - - komplikaatiot; kasvutekijät; verisuonet
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“If you can dream it, you can do it.
Always remember that this whole thing was started with a dream and a mouse.”
- Walt Disney
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1 Introduction
The prevalence of diabetes is increasing and especially type 2 diabetes is starting to reach
epidemic proportions in the Western world. Cardiovascular diseases (CVD) are the major
cause of morbidity and mortality in diabetes, and patients suffer from both micro- and
macrovascular complications. The high prevalence of concomitant cardiovascular risk
factors, the predisposition to atherogenic lipid abnormalities, and other diabetes-related
biochemical and metabolic perturbations, lead to accelerated atherosclerosis and arterial
dysfunction. Since there are no curative treatments for either diabetes or atherosclerosis,
therapeutical options are somewhat limited to symptom alleviation. In addition to
pharmacological therapies, revascularization procedures are performed to improve blood
flow in the heart and lower limbs. However, due to the often diffuse vascular disease and
complex clinical picture of diabetic patients, the response to treatment is often not optimal or
the conventional surgical procedures cannot be performed. As a new treatment modality,
gene therapy applications show promise in the treatment of CVD. In clinical trials,
therapeutical angiogenesis has proven to be safe and feasible. However, increased
neovascularization can contribute also to pathogenic processes, such as atherosclerotic lesion
growth and the development of diabetic retinopathy, and concerns about the safety of pro-
angiogenic therapies have been raised based on results from some animal studies.
Animal models are essential tools in the preclinical research of complex metabolic
disorders. In recent years, various mouse models combining disorders of lipid and glucose
metabolism have been generated and studied, and they have provided new and valuable
information. However, one major limitation of most mouse models is the fact that they do
not experience diabetic cardiovascular complications without a concomitant increase in
plasma lipid levels, which does not replicate the human situation. Therefore, new models
are urgently needed for studying the pathophysiology of both micro- and macrovascular
complications in diabetes, since this could help in the development of new therapeutic
approaches and also improving the efficacy of the current procedures.
This thesis studied the safety and pharmacodynamics of a cardiovascular gene therapy
approach in relation to atherosclerosis. Furthermore, in an attempt to create improved
research tools better mimicking diabetic cardiovascular complications, a new mouse model
was developed and characterized.
2
32 Review of the literature
2.1 DIABETES AND CARDIOVASCULAR DISEASES
2.1.1 Diabetes mellitus
Diabetes mellitus is a group of disorders characterized by abnormally high blood glucose
levels resulting either from insulin deficiency or from resistance to the action of insulin, or
from a combination of both. The two main forms are type 1 diabetes (T1D), where the
insulin-producing pancreatic beta (β) cells have been destroyed, and type 2 diabetes (T2D),
which is a metabolic disorder with a more complex etiology. Additional less prevalent
subclasses include gestational diabetes, genetic forms and secondary conditions resulting
from other pancreatic diseases or medications. The number of diabetic patients worldwide is
currently over 220 million and the number is continuously increasing (WHO, 2011). The
increase in prevalence has been most dramatic in T2D, which accounts for over 90 % of all
diabetes cases (Zimmet, Alberti & Shaw 2001). The acceleration of the diabetes epidemic is
naturally also accompanied by an increase in diabetic complications, which are the major
causes of heart disease, blindness, renal failure and lower limb amputation.
The diagnosis of diabetes is based on the criteria recommended by the World Health
Organization (Table 1) (WHO, 2005). Diagnostic cut-off points for diabetes are fasting
plasma glucose ≥7.0 mmol/l or 2-hour plasma glucose concentration ≥11.1 mmol/l in an oral
glucose tolerance test. However, glucose levels also below the diabetic threshold correlate
with  the  probability  of  developing  T2D and the  risk  of  CVD (Unwin et al. 2002). Thus the
terms impaired glucose tolerance (IGT) (WHO, 1980) and impaired fasting glucose (IFG)
(WHO 1999) have been introduced to describe the status between normoglycemia and
diabetes. This state is also called pre-diabetes, since it precedes full-blown disease in T2D
patients. However, many individuals with pre-diabetic values do not progress to diabetes,
and therefore the term “intermediate hyperglycemia” is recommended to describe IFG and
IGT (WHO, 2005).
Table 1. Diagnostic  criteria  for  diabetes  and  intermediate  hyperglycemia  (IFG  and  IGT)  (WHO
2005).   Criteria  differ  depending  on  the  sample  collection  site:  plasma  values  are  about  11  %
higher than in whole blood, and in non-fasting conditions venous whole blood gives higher results
than capillary samples. Plasma glucose (in bold) is used as the standard parameter.
Fasting glucose (mmol/l) 2-hour post-glucose load (mmol/l)
Plasma Whole blood Plasma Whole blood
(venous) Venous Capillary (venous) Venous Capillary
Normal <6.1 <5.6 <5.6 <7.8 <6.7 <7.8
IFG 6.1-6.9 5.6-6.0 5.6-6.0 and <7.8 <6.7 <7.8
IGT <7.0 <6.1 <6.1 and 7.8-11.0 6.7-9.9 7.8-11.0
Diabetes ≥7.0 ≥6.1 ≥6.1 or ≥11.1 ≥10.0 ≥11.1
IFG, impaired fasting glucose; IGT, impaired glucose tolerance.
42.1.1.1 Type 1 diabetes
T1D results from the dysfunction and destruction of pancreatic β-cells which causes an
absolute insulin deficiency and complete dependence on exogenous insulin to regulate
blood glucose levels. T1D is commonly known as juvenile-onset diabetes, as it generally
occurs before the age of 30, peaking around the time of puberty. The worldwide incidence of
childhood-onset T1D varies significantly with the highest rates (>40/100 000) being reported
from Finland (The DIAMOND Project Group 2006).
The cause of T1D remains unclear. Substantial evidence indicates that both genetic and
environmental etiological factors are involved (Borchers, Uibo & Gershwin 2010). Numerous
genetic loci have been associated with the risk for T1D and the major causal candidates have
been located in the human leukocyte antigen (HLA) region (Pociot et al. 2010). HLA
molecules are essential in the function of the immune system and account for antigen
presentation to T-lymphocytes. Accordingly, in most cases of T1D, the β-cell destruction is
autoimmune-mediated and autoantibodies exist for months or years before any clinical
manifestation (Atkinson, Maclaren 1994). The pancreatic function deteriorates gradually - it
has been estimated that at the time of diagnosis about 80-90 % of the β-cells have been
destroyed, reaching total extinction in the following 1-2 years (Foulis et al. 1986). It has also
been postulated that exposure to certain environmental factors during pregnancy,
neonatally or in early childhood could trigger the disease onset. These include e.g. certain
viral  infections,  exposure  to  cow’s  milk  antigens  and  climatic  factors  (Borchers,  Uibo  &
Gershwin 2010). In particular enterovirus infection has been shown to have a strong
association with T1D (Yeung, Rawlinson & Craig 2011). However, the distinct causal roles of
environmental triggers remain unclear. For example, early exposures to particular viral
infections could promote the development of autoimmunity, and subsequent infections in
later life would then accelerate the process. Furthermore, genetically susceptible individuals
might have an altered immune system causing generally augmented reactivity to otherwise
harmless antigens (Hirschhorn 2003).
Insulin deficiency has various effects on metabolism (Figure 1). Normally, insulin
regulates blood glucose levels by stimulating glucose uptake in peripheral tissues (mainly
skeletal muscle), increasing the storage of glucose as glycogen and by inhibiting hepatic
glucose production (Bennett 2000, Aronoff et al. 2004). In the absence of insulin, the tissue
uptake of glucose is impaired and blood glucose levels become elevated. As the glucose
concentration exceeds the renal reabsorption capacity, dehydration develops via glucosuria
and  osmotic  diuresis  and  these  cause  the  first  typical  symptoms  of  diabetes:  polyuria  and
thirst (Guyton, Hall 2006).
Insulin also promotes fat storage, inhibits lipid mobilization and regulates triglyceride
(TG) utilization (Bennett 2000). In uncontrolled diabetes, the accelerated hydrolysis of stored
TGs releases large quantities of free fatty acids (FFA) into the circulation. FFAs are then used
in the hepatic synthesis of very low-density lipoproteins (VLDL) or ketone bodies. A
prolonged excess of ketone bodies leads to ketoacidosis, which, if not corrected with
exogenous insulin, can induce unconsciousness, coma or even death (Guyton, Hall 2006).
As an anabolic hormone, insulin also facilitates the transport of amino acids into tissues,
decreases proteolysis and increases protein synthesis in liver and skeletal muscle (Bennett
2000). Thus when insulin is not available, protein catabolism is switched on and this leads to
elevated amino acid concentrations in blood. Most of the excess amino acids are used as
5substrates in hepatic gluconeogenesis, thus worsening hyperglycemia, or are excreted in
urine, inducing weight loss (Guyton, Hall 2006).
Figure 1. Metabolic actions of insulin. In normal conditions, blood glucose levels are controlled by
insulin-stimulated glucose uptake and the suppression of hepatic glucose production, and lipolysis
in fat tissue is inhibited. If insulin secretion is diminished (β-cell dysfunction) or the actions of
insulin blunted (insulin resistance), hyperglycemia and increased levels of circulating fatty acids
ensue. Modified from Stumvoll, Goldstein & van Haeften (2005).
2.1.1.2 Type 2 diabetes
T2D is a heterogeneous disorder characterized by peripheral insulin resistance (IR) and
inadequate insulin secretion, both of which are usually present at the time of clinical
manifestation. T2D accounts for by far the most diabetes cases and its global prevalence is
continuously increasing. Moreover, although T2D, also known as the adult-onset diabetes,
has long been regarded as a disease of the middle-aged and elderly, the numbers of younger,
even pediatric patients, are also steadily growing (Alberti et al. 2004).
The increase in T2D seen during the last few decades clearly highlights the significant
contribution of environmental, or lifestyle, factors – major determinants include obesity
(especially central adiposity), diet, and physical inactivity, although also the intrauterine
environment (e.g. low birth weight or mother’s diabetes) can influence the risk of future T2D
(Bennett 2000). Thus, it seems that the pathogenesis of T2D is multifactorial – genetic factors
determine the individual susceptibility but environmental factors dictate whether this
predisposition will manifest as diabetes. The genetic risk profile consists of variations in
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6many genes, which on their own are not causative, but each add slightly to the overall
genetic susceptibility (Das, Elbein 2006).
2.1.1.2.1 Insulin resistance
IR represents the hallmark of T2D. It is described as defective glucose uptake in skeletal
muscle, liver and adipose tissue in response to a normal insulin concentration. The main
mechanisms of IR involve alterations in insulin receptor expression and affinity, as well as
insulin signaling defects (Schinner et al. 2005, Pessin, Saltiel 2000). Insulin signaling is
transduced via two major pathways: metabolic and hemodynamic effects are mediated by
phosphatidylinositol-3 kinase (PI-3K) and the Ras-mitogen-activated protein kinase (MAPK)
pathway is mainly involved in gene expression regulation, cell growth and differentiation
(Avruch 1998). In IR, only the PI-3K dependent signaling is impaired; other pathways are
not affected (Cusi et al. 2000). These signaling defects can evolve as
a consequence of mutations in the insulin signaling molecules, although the extent of their
contribution is not certain (Schinner et al. 2005). Moreover, and since most insulin resistant
individuals are obese, dysfunctions in adipose tissue may play a central role in the
deterioration of insulin signaling through two distinct mechanisms (Saltiel, Kahn 2001). First,
the release of excessive amounts of FFAs from adipose tissue leads to the accumulation of
triglycerides and fatty acid-derived metabolites in skeletal muscle and liver cells, which
suppresses insulin-signaling proteins. Secondly, in addition to being an energy storage site,
adipose tissue also acts as an endocrine organ by secreting adipokines. The expression of the
so-called insulin sensitizing adipokines, such as adiponectin, is decreased in obesity, while
there is an increase in the expression of factors blunting the insulin signaling cascade,
e.g. tumour necrosis factor a (TNFa).
Although many molecular events of IR have been identified, the exact course of events is
still elusive. It is known that insulin sensitivity and insulin secretion are tightly linked and
once one of them changes, the other process adapts (Kahn 2003). However, the sequence and
pathophysiological mechanisms involving IR and hyperinsulinemia are not entirely clear. It
is generally thought that hyperinsulinemia occurs as a compensatory reaction in order to
maintain normoglycemia when peripheral insulin sensitivity is reduced. Nonetheless, also
an alternative theory of hyperinsulinemia being the primary incident has been proposed.
This is mainly based on insulin’s ability to desensitize its target cells to its own actions
(Shanik et al. 2008). Regardless of the precise pathogenesis, once IR has developed, even the
hypersecretion of insulin is not sufficient to sustain normal glucose regulation and
eventually mild postprandial hyperglycemia appears, resulting in IGT. As long as the b-cells
are able to maintain a satisfactory insulin secretion, diabetes does not develop. However,
after a period of hyperinsulinemia, insulin secretion diminishes in some individuals, leading
to overt hyperglycemia and progression to clinical T2D.
2.1.1.2.2 Impaired insulin secretion
The mechanisms behind insulin deficiency in T2D include both an inefficient secretion of
insulin and reduced b-cell mass (Weir, Bonner-Weir 2000). Impaired insulin secretion can
result from b-cell exhaustion, which develops following hyperinsulinemia and prolonged
glucose exposure. In fact, this is observed already in IGT and early T2D as a defective first
phase insulin response to a rapid glucose load, e.g. in oral or intravenous glucose challenge,
7and as a result, postprandial hyperglycemia ensues, since hepatic glucose production is not
suppressed (Caumo, Luzi 2004). Chronic hyperglycemia further deteriorates b-cell function
through glucotoxicity, which is postulated to be mediated by the production of reactive
oxygen species (ROS), the activation of endoplasmic reticulum (ER) stress and increase in
intracellular calcium (Chang-Chen, Mullur & Bernal-Mizrachi 2008). In the presence of
hyperglycemia, also elevated levels of FFAs deteriorate b-cell function and survival
(glucolipotoxicity). The overall effect of these processes impairs insulin secretion, reduces
insulin gene expression and eventually results in the apoptosis of b-cells. The reduction of
b-cell mass is a continuous process beginning already before overt diabetes. In fact,
apoptosis-mediated reductions of 41 % and 63 % in b-cell volumes have been reported in
individuals with IFG and T2D, respectively (Butler et al. 2003).
2.1.2 Cardiovascular complications in diabetes
After the onset of diabetes, most patients develop cardiovascular complications.
Microvascular dysfunction can lead to significant morbidity and premature mortality, and
macrovascular events are the leading cause of death in diabetic patients (UK Prospective
Diabetes Study Group 1998).
2.1.2.1 Macrovascular disease in diabetes
Diabetes magnifies the risk of macrovascular diseases independently of conventional risk
factors. Compared to non-diabetic individuals, the risks of developing coronary and
peripheral artery disease are more than doubled in diabetes (Abbott, Brand & Kannel 1990,
The Emerging Risk Factors Collaboration 2010). In addition, the risk of cerebrovascular
events, such as stroke, is increased about 2-fold in the whole patient population and more
than 10-fold in diabetic patients under the age of 55 (The Emerging Risk Factors
Collaboration 2010, You et al. 1997). In addition to increasing the risk of developing
macrovascular complications, diabetic patients also experience adverse outcomes with high
rates of recurrence and mortality following myocardial infarction and stroke, as well as
amputation of lower limbs (Beckman, Creager & Libby 2002).
2.1.2.1.1 Atherosclerosis
The principal pathophysiological process underlying macrovascular diseases is
atherosclerosis. Atherosclerosis is a progressive disease of the large and medium-sized
arteries with the accumulation of lipids and fibrous material in the arterial wall (Figure 2)
(Ross 1999, Lusis 2000, Libby 2002). The classical risk factors include elevated level of
low-density lipoprotein (LDL), low high-density lipoprotein (HDL) concentration, smoking,
hypertension and diabetes (Lusis 2000).
Arteries consist of three layers: intima, media and adventitia. Intima is the innermost
layer consisting of the endothelium lining the luminal surface and some smooth muscle cells
(SMC) (Stary et al. 1992). Media is an elastic muscular layer formed mainly by SMCs.
Adventitia is the outer layer of connective tissue, which stabilizes the artery and contains the
innervation and blood supply for the vessel wall. Intact endothelium is crucial for the
normal functioning of the artery and it plays important role in the regulation of blood
clotting, inflammation and vascular tone. Atherosclerosis affects primarily the sites of
8vasculature with turbulent blood flow and low shear stress, such as branches, bifurcations
and curvatures (Gimbrone 1999). Altered blood flow increases endothelial permeability and
induces the expression of adhesion molecules, thus rendering the site susceptible for the
atherosclerotic process (Ross 1999).
Figure 2.  Schematic  picture  of  different  lesion  types  in  the  development  of  atherosclerosis  and
representative histological images from human coronary arteries. E, endothelium; F, fibrous cap;
FC, foam cells; I, intima, LC, lipid core; M, media; SMC, smooth muscle cell; T, thrombus. Adapted
from Stary et al. (1992, 1995), Pepine (1998) and Atherosclerosis Image Library/Stary (available
for academic use at http://www.atherosclerosis-image-library.at).
The formation of an atherosclerotic lesion begins when LDL diffuses into the arterial wall
from the bloodstream and accumulates in the subendothelial space. Trapped LDL undergoes
oxidative modifications and stimulates the endothelial cells to produce proinflammatory
molecules, which increase the influx of leukocytes and monocytes into the artery wall.
Monocytes differentiate into macrophages that take up oxidized LDL, leading to the
formation of foam cells. These early atherosclerotic lesions are called fatty streaks. If the
inflammatory response caused by oxidized LDL does not cease, the atherosclerotic process
continues with the migration and proliferation of medial SMCs within the inflammed intima.
SMCs secrete extracellular matrix proteins, take up modified LDL and form a fibrous cap
structure. The inflammatory environment also induces the death of lipid-loaded
macrophages and SMCs, which form a necrotic core typical for more advanced lesions.
Lesions can be further complicated by calcification and neovascularization. Although the
progressive narrowing of the arterial lumen by the growing lesion can cause ischemic
symptoms, acute and clinically more serious cardiovascular events, like myocardial
infarction and stroke, usually result from plaque rupture and the following thrombosis. The
atherosclerotic plaque can rupture if the fibrous cap breaks as a result of erosion caused by
chronic inflammation. This most often happens in the shoulder regions of the plaque, which
are the sites of macrophage influx, accumulation and apoptosis. When the thrombogenic
lipid core is exposed and comes in contact with the coagulation factors of blood, thrombosis
9occurs and can occlude the artery, blocking blood flow. (Lusis 2000, Libby 2002, Glass,
Witztum 2001).
Endothelial dysfunction is considered to be the basis for the development of angiopathy
in both the micro- and macrovasculature (Calles-Escandon, Cipolla 2001). It can be defined
as disturbed adhesive properties, increased permeability and an imbalance between the
production of contracting and relaxing substances by the endothelium. Under normal
conditions, nitric oxide (NO) produced by the endothelial cells plays a pivotal role in
mediating vasodilation and other antiatherogenic effects, such as the inhibition of platelet
activation, inflammation, and SMC migration and proliferation. In the dysfunctional
endothelium, impaired production of NO, as well as increased NO inactivation by ROS,
cause decreased bioavailability of NO and the development of a proatherogenic state in the
vessel wall. Although common etiological factors, such as elevated cholesterol levels
(Drexler et al. 1991), smoking (Heitzer et al. 1996) and hypertension (Panza et al. 1990),
contribute to the development of endothelial dysfunction and subsequent atherogenesis,
there are also pathogenic mechanisms specific to diabetes (Figure 3) (Sitia et al. 2010).
Figure 3. Diabetic metabolic abnormalities promote atherogenesis by inducing oxidative stress,
activating signaling cascades (e.g. PKC) and inducing the formation of advanced glycation end
products (AGEs), which lead to the dysfunction of the endothelium, platelets and vascular
endothelial growth factors (VEGF). Together with diabetic dyslipidemia, these changes accelerate
atherogenesis and create a pro-thrombotic state, exposing the individual to the risk of serious
cardiovascular events. AT-II, angiotensin II; ET-1, endothelin-1; HDL, high-density lipoprotein;
NF-kB, nuclear factor kappa B; NO, nitric oxide; PAI-1, plasminogen activator inhibitor-1; PKC,
protein kinase C; sdLDL, small dense low-density lipoprotein; TF, tissue factor; TG, triglycerides;
VLDL, very low-density lipoprotein. The conceptual idea for the figure was obtained from Creager
et al. (2003).
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The main factor underlying the increased risk of CVD in diabetes is accelerated
atherosclerosis. In diabetes, atherosclerosis also develops earlier and is usually more severe
and diffuse than in non-diabetic patients (Goraya et al. 2002). Although the precise
mechanisms by which diabetes leads to more aggressive atherosclerosis are still undefined,
several factors contributing to the pathogenesis of diabetic macrovasculopathy have been
clarified.
2.1.2.1.1.1 Atherogenic effects of hyperglycemia
The correlation between blood glucose levels and the risk of cardiovascular events has been
clearly demonstrated in epidemiological studies (Coutinho et al. 1999). Although the effect of
intensive glycemic control on the prevention of macrovascular disease is less profound than
on  the  reduction  of  microvascular  complications  (Ray et al. 2009), it is evident that
hyperglycemia has many detrimental effects on the macrovasculature and it promotes
atherogenesis.  While  most  cell  types  are  able  to  reduce  glucose  uptake  when exposed  to  a
high concentration of this carbohydrate, some other cells (such as endothelial cells,
glomerular mesangial cells, neurons and Schwann cells in peripheral nerves) are not able to
effectively regulate the intracellular glucose concentration, making them vulnerable to
hyperglycemia-induced damage (Brownlee 2005).
Based on the current knowledge, the central mechanism mediating the harmful effects of
a high glucose concentration on cells is thought to be increased oxidative stress and
subsequent mitochondrial production of ROS (Brownlee 2005) (Figure 3). This decreases the
metabolism of glucose through glycolysis, and the flux through the alternative polyol and
hexosamine pathways is increased. The accumulation of glycolytic intermediates activates
the protein kinase C (PKC) pathway, and this induces the formation of advanced glycation
end products (AGE). The overall effects of these mechanisms are increased oxidative stress,
apoptosis and vascular permeability. Pro-inflammatory gene expression is stimulated
through the activation of transcription factors such as nuclear factor kappa B (NF-kB,
nuclear factor kappa-light-chain-enhancer of activated B cells), leading to an increased
production of adhesion molecules, leukocyte-attracting chemokines and cytokines activating
inflammatory cells in the vascular wall. A pro-thrombotic state is generated by the increased
production of lesion-based coagulants, such as tissue factor, and the inhibitors of fibrinolysis,
such as plasminogen activator inhibitor-1. Vascular remodeling and vasomotor tone are
enhanced through reduced NO and an increased activity and production of vasoconstrictors,
e.g. endothelin-1. (Creager et al. 2003, Brownlee 2005, D'Souza et al. 2009). Although greatly
induced by hyperglycemia, these central pathogenetic mechanims are not specific only to
hyperglycemia but are promoted also by other metabolic abnormalities present in diabetes.
The glycosylation of proteins and lipids in the arterial wall is a normal and continuous
physiological process, which is directly dependent on the blood glucose concentration.
AGEs are irreversible compounds formed when reactive glucose intermediates non-
enzymatically react with nucleic acids, transcription factors and intracellular or extracellular
proteins (Brownlee 2001). Glycation alters the structure of the molecules and thus disturbs
their function and receptor recognition properties. For example, the glycation of
apolipoprotein B in the LDL particle reduces the clearance of LDL (Bucala et al. 1995), and
glycated phospholipids render the LDL particle more susceptible to oxidative modifications
(Bucala et al. 1993), thus making the LDL more atherogenic. Through the activation of their
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receptor (RAGE), AGEs also initiate signaling cascades which potentiate the effects of
hyperglycemia. (D'Souza et al. 2009, Brownlee 2001, Aronson, Rayfield 2002).
The consequences of hyperglycemia are seen also in the plaque structure, where medial
SMCs play an important role. As the plaque develops, SMCs migrate from media to intima
and strengthen the plaque by forming a fibrous cap and synthetizing collagen. Vascular
SMCs from diabetic patients exhibit increased proliferation, adhesion and migration (Faries
et al. 2001), which might provoke accelerated lesion development. However, it has been
observed that ruptured plaques in general and also the advanced lesions of diabetic patients
contain fewer SMCs than the stable plaques or lesions of non-diabetic patients (Fukumoto et
al. 1998, Libby 2001). One possible reason for this is SMC apoptosis induced by oxidized
LDL (Taguchi, Oinuma & Yamada 2000), a process which is enhanced by the hyperglycemic
oxidant milieu. Additionally, hyperglycemia-induced endothelial cytokine and proteinase
production have been reported to promote plaque destabilization through decreasing the
production and increasing the breakdown of collagen (Death et al. 2003). Despite the
possible stabilizing effect of SMCs, they are also believed to be essential in the development
of intimal hyperplasia and the subsequent restenosis, as well as in the negative remodeling
of arteries, both of which have been observed to be increased in diabetic patients
(Kornowski et al. 1997, Gilbert, Raboud & Zinman 2004) and to worsen the outcome of
revascularization procedures. Moreover, unlike in vulnerable atherosclerotic lesions, in
intact diabetic human arteries, downregulated apoptosis and an excessive accumulation of
extracellular matrix have been noted (Chung et al. 2007), emphasizing the complexity and
versatility of the effects created by diabetes in different types and different phases of the
vascular injury.
In addition to worsening the endothelial dysfunction and accelerating atherogenic
processes, hyperglycemia predisposes the individual to thrombosis. This is mediated
through the effects on the vascular wall and the plasma components of coagulation, but also
through a direct influence on platelet function. Platelets of diabetic patients have been
observed to represent a hyperreactive phenotype with increased adhesion, activation and
aggregation. Hyperglycemia induces these changes by various mechanims including AGE
formation and PKC activation, although also IR and dyslipidemia contribute to platelet
hyperreactivity. (Ferreiro, Gomez-Hospital & Angiolillo 2010).
2.1.2.1.1.2 Insulin resistance in atherogenesis
IR  is  an  independent  risk  factor  for  CVD  (Bonora et al. 2002). IR causes proatherogenic
effects via multiple mechanisms (Figure 3). Firstly, it promotes endothelial dysfunction and
a  prothrombotic  state.  Normally,  insulin  stimulates  NO  production  in  endothelial  cells  by
activating NO synthase via the PI-3K pathway. In IR this pathway is impaired, and therefore
the production of NO is diminished (Kim et al. 2006) and its beneficial effects are lost. In
addition to the direct effects of IR on the endothelium, IR in adipose tissue is associated with
elevated circulating levels of plasminogen activator inhibitor-1 (PAI-1), which contributes to
the impaired fibrinolysis (Trost, Pratley & Sobel 2006). Secondly, IR leads to an excessive
release of FFAs from adipose tissue, which evokes pathogenic gene expression through PKC
activation and increased oxidative stress (Inoguchi et al. 2000). In parallel, the IR-induced
excess of FFAs is essential also in the development of dyslipidemia, which further promotes
the development of a proatherogenic lipid profile; this will be discussed in more detail
below. Thirdly, at the cellular level, IR in macrophages promotes the uptake of atherogenic
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lipoproteins and foam cell formation, as well as increases macrophage apoptosis and
impairs their ability to phagocytose cellular waste in the atherosclerotic lesions (Liang et al.
2007), thus increasing the size of the necrotic core and making the plaques more prone to
rupture.
2.1.2.1.1.3 Diabetic dyslipidemia
Both T1D and T2D are associated with lipid abnormalities that promote atherogenesis,
although they are much more prevalent in T2D. While some differences exist, a common
pattern of dyslipidemia is descriptive for both types of diabetes: elevated TGs, low total
HDL and small, dense LDL (sdLDL) particles (Figure 3).
In T2D, IR is the main pathogenetic mechanism underlying the lipid abnormalities and its
actions are mediated through effects on both adipose and hepatic tissues. An increased
hepatic influx of FFAs enhances the production of VLDL, which when IR is present, cannot
be suppressed by insulin. VLDL is normally catabolized by lipoprotein lipase (LPL), which
hydrolyzes TG-rich particles. However, when VLDL levels are high, LPL becomes saturated,
leading to reduced VLDL catabolism and a longer plasma half-life of the VLDL particles. As
a consequence, there is accelerated lipid exchange between the TG-rich VLDL particles and
lower density lipoproteins by cholesterol ester transfer protein (CETP). This results in highly
atherogenic cholesterol-enriched VLDL remnants, and TG-rich LDL and HDL particles.
These LDL and HDL particles are susceptible to lipolysis by hepatic lipase, with the end
result being the formation of small, dense HDL and LDL. The HDL of this form is cleared
more rapidly and is less able to perform reverse cholesterol transport, which is the main
mechanism for removal of cholesterol from extrahepatic tissues to the liver for excretion. In
turn, the sdLDL particles demonstrate increased atherogenicity – they enter the arterial wall
more easily than larger LDL, their plasma half life is prolonged due to decreased receptor-
mediated uptake and they are more susceptible to oxidative modifications. On the whole,
the TG concentration is elevated, the levels and cardioprotective characteristics of HDL are
decreased, and there is a shift towards an increased number of more atherogenic LDL
particles and VLDL remnants. (Betteridge 2000).
In T1D, the lipid abnormalities are clearly related to the level of glycemic control. In
untreated T1D, or diabetic ketoacidosis, the elevation in FFAs increases the VLDL
concentration. Simultaneously, the catabolism of VLDL particles is diminished, because LPL
activity is decreased due to the lack of insulin stimulation and consequently, the levels of
LDL and HDL are also decreased. If diabetes is treated but glycemic control is poor, elevated
TG levels may persist and in addition, since VLDL catabolism is less decreased due to the
partly preserved LPL activity, also elevated LDL levels may occur. However, these
abnormalities can be abolished by insulin treatment and in good glycemic control, the
situation is normalized: TG and LDL levels are normal or even reduced, and the HDL
concentration is normal, or sometimes elevated. (Verges 2009).
The atherogenic effects of diabetic dyslipidemia are diverse. In epidemiological studies,
hypertriglyceridemia is found to be a strong and independent risk factor for CVD (Cullen
2000), although the association between sdLDL and CVD is also clear (Carmena, Duriez &
Fruchart 2004, Rizzo, Berneis 2007). Both TG-rich lipoproteins and sdLDL particles have
been shown to be atherogenic in vitro. Therefore, it is somewhat unclear if the increased risk
observed in hypertriglyceridemia is caused by direct atherogenic effects of the cholesterol-
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enriched VLDL particles, or if it reflects the overall effects of hypertriglyceridemia on the
lipid metabolism, including decreased HDL levels and the formation of sdLDL (Cullen 2000).
2.1.2.1.2 Angiogenic paradox in diabetes
In conjunction with the excessive atherosclerosis, additional factors exist that increase the
CVD burden in diabetic patients. An abnormal regulation of neovascularization plays an
essential role in the vascular complications of diabetes (Simons 2005).
Enhanced angiogenesis, i.e. capillary vessel growth in response to hypoxia, can
potentially promote the destabilization of atherosclerotic plaques (Khurana et al. 2005) and is
the main mechanism underlying the development of diabetic retinopathy (Nguyen, Wong
2009). On the other hand, insufficient angiogenesis hinders wound healing and thus
contributes to the emergence of diabetic ulcers (Brem, Tomic-Canic 2007). With respect to
macrovascular diseases, the main abnormality worsening the clinical picture is defective
arteriogenesis (Figure 3). Arteriogenesis is defined as an increase in the diameter of
pre-existing arterioles and arteries, and is crucial in the development of collateral vessels in
response to arterial occlusion both in the myocardium and lower extremities. A reduced
number of collateral vessels has been reported in diabetic patients (Abaci et al. 1999,
Waltenberger 2001) and there is experimental data showing that their number is also
reduced in ischemic hind limbs of diabetic mice (Yan et al. 2009a). The defect seems to be
more severe in T2D than in T1D (Yan et al. 2009a), probably reflecting the additional
deteriorating effects of dyslipidemia and other metabolic disturbances which are more
prevalent in T2D. Impaired collateral formation leads to worse outcome and poorer recovery
after myocardial and peripheral ischemia, accounting to some extent for the increased
cardiac mortality and the need for amputation.
The underlying mechanisms of unbalanced neovascularization in diabetes have not been
fully elucidated. There are findings indicating defects in signaling of the most potent
promoter of vascular growth, vascular endothelial growth factor (VEGF). VEGF-A is
essential for embryonic vasculogenesis and in adults it is needed for the maintenance of
vascular homeostasis as well as tissue regeneration after injury and ischemia (Ylä-Herttuala
et al. 2007). It has been postulated that low levels of VEGF-A are crucial for its
vasculoprotective effects, such as the maintenance of vascular integrity, NO production and
the suppression of SMC proliferation, whereas angiogenic effects, either physiologic or
pathologic, occur only with markedly higher concentrations of this factor. In diabetic CAD
patients, increased myocardial VEGF expression, but a reduced expression and decreased
activation of VEGF receptors have been observed as compared to the situation in
non-diabetic subjects (Sasso et al. 2005). Glycosylation-mediated inactivation of signal
transducers has been suggested as a possible mechanism for the impaired VEGF effects in
endothelial cells (Luo, Soesanto & McClain 2008), and an elevated baseline activity of
signaling effectors and subsequent resistance to further VEGF stimulation have been
observed in monocytes (Tchaikovski et al. 2009). In addition to these disturbances with
VEGF effects, diabetes is associated with a reduced number and impaired function of
endothelial progenitor cells (EPC), which have been proposed to contribute to
neovascularization in ischemic tissues (Tepper et al. 2002, Loomans et al. 2004). However, the
net effect of this finding on CVD remains obscure, since in some animal studies, the EPCs
have also been associated with the progression of atherosclerosis (Khurana et al. 2005, Aicher,
Zeiher & Dimmeler 2005).
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2.1.2.1.3 Metabolic abnormalities in the diabetic heart
Diabetes induces metabolic changes in the heart that contribute to the increased
susceptibility to functional defects and to the poor recovery from ischemic events. The heart
is capable of using a variety of substrates to fulfill its continuous need for energy and the
metabolic preference varies depending on substrate availability and physiological
conditions (e.g. workload, oxygen availability). Under normal conditions, 60-70 % of energy
comes from FFAs with the rest being derived mainly from carbohydrates, whose influx into
cardiomyocytes is mediated by insulin-stimulated glucose transporters. In diabetes, a switch
from glucose further to FFAs occurs, so that up to 90-100 % of energy is being derived from
FFAs (Lopaschuk 2002). This might partially be due to blunted insulin action affecting
glucose transport as well as the regulation of fatty acid oxidation, although it has been noted
that despite a profound peripheral IR, the myocardium of diabetic patients maintains
relatively intact responsiveness to insulin (Utriainen et al. 1998). Since fatty acids are less
efficient  as  an  energy  source  requiring  more  oxygen  than  glucose  to  produce  the  equal
amount of energy, this switch decreases cardiac efficiency. While in a stressed state, the
heart normally switches to glucose usage, in diabetes it is no longer able to modulate its
substrate selection, rendering it extremely sensitive to changes in oxygen availability. As the
blood flow in ischemic conditions is reduced, this impairs the transport of substrates, and
the energy is provided mainly by anaerobic glycolysis. If and when reperfusion occurs, the
recovery will be the better the more energy can be produced by glucose oxidation
(Lopaschuk 2002). Therefore, the diabetic heart is less able to resist ischemic conditions and
the recovery after an ischemic event is impaired.
2.1.2.1.4 Diabetic cardiomyopathy
Although accelerated atherosclerosis plays a major role in the increased cardiovascular
mortality in diabetes, there is epidemiological data indicating that diabetes increases the risk
of cardiac dysfunction and heart failure also independently of the coexistence of coronary
artery disease (CAD), hypertension, or other macrovascular risk factors (Fang, Prins &
Marwick 2004). The term diabetic cardiomyopathy (DCM) has been introduced to describe
this distinct clinical entity characterized by the functional (primarily diastolic dysfunction)
and structural (hypertrophy) changes in the left ventricle, leading to heart failure.
Although the pathophysiological mechanisms leading to DCM are still elusive, several
associated factors have been proposed. Hyperglycemia has been shown to strongly relate to
the incidence of DCM (The Diabetes Control and Complications Trial Research Group 1993).
It is considered to be the underlying factor triggering other contributing changes such as
myocardial metabolic disturbances, microangiopathy and myocardial fibrosis. In fact, it is
the microvascular changes that can cause reduced myocardial perfusion and subsequent
ischemia, and therefore the categorization of DCM into micro- or macrovascular
complications is unclear.
2.1.2.2 Microvascular disease in diabetes
The microvasculature consists of arterioles, capillaries and venules. Their function is to
regulate tissue perfusion, provide exchange surface between plasma and tissues and to
regulate blood pressure (Ko, Cao & Liu 2010). Hyperglycemia is the single most important
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factor behind microvascular diseases and there is clear evidence about the benefit of good
glycemic control in the prevention and delay of microvascular complications in both T1D
and T2D (UK Prospective Diabetes Study Group 1998, The Diabetes Control and
Complications Trial Research Group 1993).
The microvascular disease associated with diabetes particularly damages those organs
whose blood supply depends heavily on the microvasculature: retina, kidneys and
peripheral nerves. Despite the differences in target organs, the main pathophysiological
characteristics in the development of microvascular complications are similar. As is the case
in the macrovasculature, hyperglycemia disturbs the regulation of vascular tone and
increases permeability also in the microvessels. After prolonged exposure to elevated levels
of glucose, the overproduction of extracellular matrix and the deposition of extravasated
plasma proteins start to occlude capillaries, and there is death of microvascular cells. In the
retina, this leads to the loss of neuronal cells and pericytes, edema, ischemia and hypoxia-
induced neovascularization, manifest as diabetic retinopathy. In the kidneys, podocyte loss,
increase in mesangial matrix, glomerulosclerosis and glomerular hyperfiltration lead via
microalbuminuria to proteinuria, manifest as diabetic nephropathy. In the peripheral nerves,
a dysfunction of the microvasculature supplying the nerves causes neuronal ischemia and
multifocal axonal degeneration, underlining the defects characterizing diabetic neuropathy.
(Brownlee 2001, Orasanu, Plutzky 2009).
Microvascular dysfunction also affects the heart and skeletal muscle, which both contain
an extensive microvascular network. Capillary rarefaction, i.e. the reduction in the number
of perfused capillaries, has been observed in skeletal muscle samples of subjects with T2D
(Levy et al. 2008). In addition to lowering the threshold for ischemia, impaired microvascular
perfusion might further reduce glucose uptake in the muscle and thus worsen IR.
Myocardial microvascular abnormalities have been associated with the development of
diabetic cardiomyopathy and might also underlie the impairment in coronary flow reserve,
which is characteristic to diabetic patients even in the absence of detectable coronary
stenosis (Fang, Prins & Marwick 2004, Levy et al. 2008). This intersection of micro- and
macrovascular pathologies is a concrete example highlighting the complexity of diabetes
and emphasizes the nature of (especially type 2) diabetes as a vascular disease.
2.2 MOUSE MODELS OF DIABETES AND CARDIOVASCULAR DISEASE
Whereas cell culture and other in vitro studies provide information on specific matters
relating to a certain disease, many etiological processes and therapeutical responses need to
be studied in a living organism, in vivo, where relevant physiological conditions and
interactions between different cell type and tissues exist. The animal model of a disease can
be homologous, i.e. having the same cause, symptoms and treatment options as humans
with the same disease. Predictive models, on the other hand, display the symptoms of a
human  disease  without  a  known  cause  and  can  be  used  for  etiological  studies  and  the
screening of candidate disease genes. However, most models are isomorphic, since the
etiology of experimentally induced disease often differs from that of spontaneously
occurring disease in man. Nevertheless, isomorphic models present symptomatic
resemblance to the human disease, share the same treatment options and are thus useful in
experimental and translational research.
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In an attempt to simulate the pathophysiological events in humans, some modification of
the animal model is often required due to physiological and metabolic differences. Thus,
genetic manipulation, dietary and/or chemical induction are typically used to improve the
applicability of laboratory animals as disease models. Mice are the most widely used
experimental animals in biomedical research for various reasons: their genome has been
sequenced (Mouse Genome Sequencing Consortium 2002), available and workable, and
inbred strains are genetically uniform, which reduces variance in the study populations.
Mice are cost-effective, easy to maintain, and suitable by their lifespan for research purposes.
Their general biology is closely comparable to that of humans, although some relevant
differences do exist that should be taken into consideration when using mice in diabetic
cardiovascular research (Table 2). However, the wide availability of techniques to modify
the mouse genome has provided an abundance of transgenic and knock-out models for
different research applications.
Table 2. Major pathophysiological differences between human and mouse relevant in studying
cardiovascular diseases. Modified from Goldberg & Dansky (2006) and Getz (2007).
Characteristic Human Mouse
Life span (years) » 80 » 2-3
Heart rate (beats/minute) 60-80 > 300
Normal diet High fat, high cholesterol Low fat, low cholesterol
Plasma cholesterol (mmol/l) » 5.0 » 2.0
Major lipoprotein LDL HDL
Cholesterol synthesis (mg/day/kg) 10 160
Hepatic LDL clearance (ml/day/kg) 12 500
ApoB subtypes in liver B100 B48 and B100
Apo(a) expression Yes No
CETP Yes No
HDL in disease Reduced in T2D Not reduced in obesity/IR
Acute phase protein CRP SAA, SAP
Age of disease manifest
Type 1 diabetes
Type 2 diabetes
Cardiovascular diseases
Early adult
Middle aged to older
Middle aged to older
Young adult
Young adult
Young adult
Aortic sinus atherosclerosis No Common
Coronary artery atherosclerosis Common Rare
Hypertension Common No
Apo, apolipoprotein; CETP, cholesterol ester transfer protein; CRP, C-reactive protein; HDL, high-density
lipoprotein; LDL, low-density lipoprotein; SAA, serum amyloid A; SAP, serum amyloid P.
In recent years, considerable input has been put into developing animal models for
diabetic complications. In addition to vigorous research, joint undertakings such as the
“Animal Models of Diabetic Complications Consortium” (AMDCC) by the National
Institute of Health in the United States, and the consortium of “Surrogate markers for
Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools” (SUMMIT) by
Innovative Medicines Initiative in the European Union address this matter. Because of the
variety of models used in the literature and the major impact of the model selection on study
results, knowledge about the basic aspects of different models is crucial for choosing the
appropriate model for each study set up and for the interpretation of the results.
2.2.1 Diabetic atherosclerosis models
Mice are naturally very resistant to atherosclerosis due to species-specific characteristics of
lipoprotein  metabolism.  In  humans,  the  most  abundant  apolipoprotein  (apo)  B  subtype  is
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apoB100, which is produced only in the liver and is the major protein component in VLDL,
LDL and intermediate-density lipoprotein (IDL) particles. The minor subtype is apoB48,
which is synthetized in the intestine and functions as a part of chylomicrons transporting
ingested lipids into the liver. However, some rodents, like rats and mice, are able to produce
apoB48 also in the liver (Greeve et al. 1993). Therefore the majority (~70 %) of all apoB in
mice is apoB48, in contrast to apoB100 in humans. In addition, in mice, the clearance of LDL
is much faster than in humans (Dietschy, Turley 2002). Mice also lack CETP activity, which
in humans transfers cholesterol esters from HDL to atherogenic LDL and VLDL particles,
and effectively lowers HDL levels (Hogarth, Roy & Ebert 2003). Consequently, in mice ~90 %
of cholesterol is carried in HDL and only a fraction in proatherogenic LDL and VLDL
(Figure 4). Nevertheless, once mice have plasma cholesterol levels of over ~5.0 mmol/l and
the cholesterol is primarily in non-HDL particles, they will eventually develop
atherosclerosis. However, genetic modification is needed to achieve this status.
The most common hyperlipidemic mouse models include the apolipoprotein E knock-out
mouse (ApoE-/-)  and the mouse deficient in LDL receptor (LDLR-/-). ApoE-/- mouse was one
of the first models developed to study atherosclerosis (Plump et al. 1992, Piedrahita et al.
1992). The depletion of apoE results in the accumulation of cholesterol-rich remnant
particles, causing a ~4-fold increase in total cholesterol levels and the formation of
atherosclerotic lesions throughout the aortic tree. However, when compared to humans,
ApoE-/- mice have a very different remnant-like lipoprotein profile (Figure 4) and lack all the
functions of apoE on cholesterol homeostasis, cellular cholesterol efflux and inflammatory
responses (Curtiss, Boisvert 2000). The LDLR-/- mice were developed quite concurrently with
ApoE-/- mice (Ishibashi et al. 1993). Although in humans LDLR deficiency leads to a
syndrome called familial hypercholesterolemia with the onset of profound atherosclerosis
already in childhood (Goldstein, Brown 1989), the phenotype of the LDLR-/- mouse  is
notably milder, since mice are able to uptake lipoproteins also via the LDLR related protein
receptor. Thus, the resulting twofold increase in total cholesterol is not sufficient to induce
lesion development in the LDLR-/- mice without a high-fat diet. Due to these shortcomings,
modifications have been made into these models. The synthesis of apoB48, the predominant
apoB  form  in  mice,  has  been  inhibited  in  both  ApoE-/- and LDLR-/- backgrounds  either  by
targeted mutations (Véniant et al. 1998, Véniant et al. 2000) or by preventing the enzymatic
editing of apoB mRNA (Powell-Braxton et al. 1998, Osuga et al. 1997). If all these models are
considered, then it is the LDLR-/- mouse synthetizing only apoB100 (LDLR-/-ApoB100/100 and
LDLR-/-Apobec-1-/- mice) that best represents the human-like lipoprotein profile (Figure 4).
The development of murine models describing diabetic macrovascular diseases has been
challenging and at present there is no perfect model of the human disease. However,
numerous models have been generated that each possess specific attributes making them
useful for studying both the mechanistic and therapeutic aspects of the vascular
complications of diabetes. In view of the expanding diabetes epidemic worldwide, any new
information from animal models is positive, even if the model does not perfectly represent
the human condition; however, translation into human conditions should be done
cautiously.
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Figure 4. Distribution of cholesterol within the size-fractionated plasma lipoproteins in A) humans
and a normal mouse, and B) in genetically modified hyperlipidemic mouse models with either
ApoE-/- or LDLR-/- background. Adapted from Véniant, Withycombe & Young (2001) and
Steenbergen et al. (2010).
2.2.1.1 Atherosclerosis models with chemically induced diabetes
Some chemical agents are able to induce a diabetic state in experimental animals. Alloxan
and streptozotocin (STZ) are toxic glucose analogues, which accumulate in pancreatic b-cells.
Their cytotoxicity is mediated via the production of ROS (alloxan) or alkylating properties
(STZ), which cause b-cell death leading to insulinopenic diabetes with hyperglycemia.
Because of the better stability, specificity and dose-response reproducibility, STZ is used
more commonly (Lenzen 2008). However, STZ does not fully replicate T1D since it usually
does not induce ketosis and treated mice do not require insulin therapy. Some of the
atherosclerosis studies using chemically induced diabetes are summarized in Table 3.
Kunjathoor et al. (1996) were the first to study the effects of STZ-induced diabetes on
atherosclerotic lesion development in mice. They found that STZ alone did not induce lesion
formation, but when combined with an atherogenic diet, hyperglycemia accelerated lesion
initiation in Balb/c but not in C57Bl/6 mice. However, in these strains, the observed lesions
were limited only to the early stages of fatty streaks. Therefore, to generate a more
human-like atherosclerosis, mice with modified lipid metabolism have mostly been used in
subsequent experiments.
Park et al. (1998) reported the use of STZ in atherosclerotic ApoE-/- mice. Hyperglycemic
ApoE mice showed accelerated lesion development and at the level of aortic sinus an over
5-fold increase in the lesion area. STZ treatment also caused a significant elevation in total
plasma cholesterol level, which most probably had some atherogenic influence. However,
accelerated lesion development could be fully suppressed by soluble RAGE in a
lipid-independent manner. This was interpreted to highlight the atherogenic impact of
hyperglycemia, although subsequently soluble RAGE has been established also to have
general anti-inflammatory properties beyond its effects on hyperglycemia (Yan et al. 2009b).
Since the study of Park and colleagues, ApoE-/- mice with STZ have been widely used in the
studies of diabetic atheroclerosis and the model has been well characterized (reviewed in
Wu & Huan 2007). The focus of these studies has been on exploring the effects of various
anti-hypertensive, hypolipidemic and anti-diabetic agents on diabetic atherosclerosis and
elucidating the mechanisms of accelerated atherosclerosis. The role of oxidative stress has
been investigated in STZ-injected ApoE-/- mice lacking the antioxidant enzyme glutathione
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peroxidase-1 (ApoE-/-GPx1-/- mice) (Lewis et al. 2007). The lack of GPx1 further increased
lesion development in the diabetic context, emphasizing the importace of antioxidant
defense in diabetes-associated atherosclerosis. However, one major drawback of STZ
diabetes is the abovementioned secondary hyperlipidemia - in most studies concomitant
elevations in lipids in diabetic versus non-diabetic ApoE-/- mice have arisen and these
changes are exacerbated if high-fat diets are used. Only in two studies, both with normal
diets, did STZ diabetes not significantly increase cholesterol or TG levels, but nevertheless
increased not only lesion development as such (Lewis et al. 2007, Tse et al. 1999) , but also the
amount of calcified lesions (Tse et al. 1999).
When  STZ  was  used  in  LDLR-/- mice for the first time, no diabetes-induced changes in
plasma lipids or atherosclerosis were noted (Reaven et al. 1997). This was most probably due
to the extremely long period of atherogenic diet (6 months), during which the lesion
development perhaps plateaued in the presence of exceptionally high cholesterol levels and
the  possible  effects  of  hyperglycemia  were  masked.  Subsequently,  by  using  a  more
short-term (6 weeks) dietary induction of hyperlipidemia, it was found that STZ does
accelerate lesion initiation in LDLR-/- mice,  although  this  was  accompanied  again  by
elevations in the levels of cholesterol and TG (Keren et al. 2000, Vikramadithyan et al. 2005).
This  has  also  been  the  case  in  LDLR-/-Apobec-1-/- mice (Hammad et al. 2003). Since
conclusions from studies with such lipid changes are suspect, other strategies have been
pursued in attempts to avoid this problem. Goldberg et al. (2004) modified the LDLR-/- mice
to present a more human-like lipoprotein profile by crossing them with apolipoprotein AI
deficient mice. When the mice were fed a low-fat, high-cholesterol diet, STZ diabetes did not
result in lipid changes, but neither did it affect lesion development.
To unravel potential mechanisms explaining the difficulties in reproducing
diabetes-accelerated atherosclerosis in mice, the role of aldose reductase (AR) has been
investigated in STZ-induced hyperglycemia. AR mediates the generation of toxic products
from glucose and is normally expressed at much lower levels in mice than humans.
Therefore the lack of AR was proposed to be one possible factor hindering the manifestation
of the vasculotoxic effects of hyperglycemia. Vikramadithyan et al. (2005) used both LDLR-/-
and LDLR+/- mice which were crossed with mice expressing human AR. They found that
only in the presence of hyperglycemia, did the expression of hAR increase atherosclerosis
and this occurred in both backgrounds. Recently, a similar finding was made also in ApoE-/-
background (Vedantham et al. 2011). Despite these consistent results, the role of AR is not
totally straightforward - conflicting results pointing to a protective role for AR in diabetes-
associated atherosclerosis were reported by Srivastava et al. (2009), who found that AR
deficiency reduced lesion formation in STZ diabetic ApoE-/- mice.
In addition to the traditional atherosclerosis models, the effects of STZ diabetes have been
studied also in other settings. Kako et al. (1999) used mice over-expressing human apoB
(HuB). When fed a Western diet, diabetic HuB mice had less lesions despite increased lipid
levels. However, in a later study, this finding was not reproduced, as STZ caused no changes
in lipids or atherosclerosis in HuB mice (Kako et al. 2002). The authors then sought to modify
the model towards a more human-like lipid profile and generated HuB mice with a
heterozygous deletion of LPL (Kako et al. 2002). In this model, both increased plasma lipids
and greater lesion amount were observed after STZ. Surprisingly, the induction of CETP
expression in these diabetic HuB/LPL+/- mice reduced both hyperlipidemia and
atherosclerosis. It was speculated that although CETP expression had caused an expected
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reduction in HDL levels, the HDL level was still sufficiently high to provide antiatherogenic
protection.
Table 3. Atherosclerotic mouse models with chemically induced diabetes. The conceptual idea for
the table was obtained from Goldberg & Dansky (2006) and Wu & Huan (2007).
Mouse model Inducer DM
Hyper-
lipidemia
Athero-
sclerosis
Comments Reference
Diabetes does not affect atherosclerosis
C57Bl/6J STZ + AD
(12-20 wks)
1 TC­ (7.5 mM)
TG« (0.2 mM)
« Cholate Kunjathoor,
1996
LDLR-/- STZ + AD
(6 mos)
1 TC« (25.1 mM)
TG« (4.6 mM)
« Reaven, 1997
HuB STZ + WD
(18wks)
1 TC­ (14.0 mM)
TG« (2.5 mM)
¯ Kako, 1999
HuB STZ + WD
(20 wks)
1 TC« (9.7 mM)
TG« (2.0 mM)
« Kako, 2002
HuB/LPL+/-CETP STZ + WD
(20 wks)
1 TC« (8.8 mM)
TG« (3.1 mM)
« Kako, 2002
LDLR-/-ApoAI-/- STZ + CD
(11 wks)
1 TC« (10.4 mM)
TG« (0.9mM)
« Goldberg, 2004
LDLR+/- STZ + HFHC
(1 mo)
1 TC­ (21.4 mM)
TG« (1.3 mM)
« Cholic acid Berti, 2005
LDLR+/-CETP STZ + HFHC
(1 mo)
1 TC­ (23.4 mM
TG« (1.3 mM)
« Cholic acid Berti, 2005
ApoE-/- Gold
thioglucose
2 TC­ (19.8 mM)
TG­ (1.1 mM)
¯ x 2.5 Leptin ­ Lyngdorf, 2003
Diabetes affects atherosclerosis and alters plasma lipid levels
Balb/c STZ + AD
(12-20 wks)
1 TC­ (9.8 mM)
TG­ (0.6 mM)
­ x 17 Cholate Kunjathoor,
1996
ApoE-/- STZ 1 TC­ (35.3 mM)
TG« (1.7 mM)
­ x 5 sRAGE ®
lesions ¯
Park, 1998
LDLR-/- STZ + WD
(6 wks)
1 TC­ (44.3 mMl)
TG­ (6.3 mM)
­ x 6.5 Keren, 2000
HuB/LPL+/- STZ + WD
(20 wks)
1 TC­ (13.8 mM)
TG­ (5.5 mM)
­ x 14 Kako, 2002
LDLR-/-Apobec-1-/- STZ 1 TC­ (9.9 mM)
TG« (1.6 mM)
­ x 1.5 Hammad, 2003
LDLR-/- STZ + HCD
(12 wks)
1 TC­ (91.6 mM)
TG« (1.3 mM)
­ x 3 Vikramadithyan,
2005
LDLR-/-hAR STZ + HCD
(12 wks)
1 TC­ (95.2 mM)
TG« (1.0 mM)
­ x 4 vs. LDLR-/- +
STZ: lipids «,
lesions ­ x 2
Vikramadithyan,
2005
Diabetes affects atherosclerosis without changes in plasma lipids
ApoE-/- STZ 1 TC« (9.1 mM)
TG« (1.3 mM)
­ x 2 Calcified
lesions
Tse, 1999
ApoE-/-GPx1-/- STZ 1 TC« (13.8 mM)
TG« (2.1 mM)
­ x 4 Lewis, 2007
LDLR+/- STZ + CCA
(12 wks)
1 TC« (14.1 mM)
TG« (0.6 mM)
­ Cholic acid Vikramadithyan,
2005
LDLR+/-hAR STZ + CCA
(12 wks)
1 TC« (13.6 mM)
TG« (0.6 mM)
­ x 2 Cholic acid;
vs. LDLR+/- +
STZ: lipids «,
lesions ­ x 2
Vikramadithyan,
2005
ApoE-/-hAR STZ 1 TC« (31.1 mM)
TG« (3.1 mM)
­ x 2 Vedantham,
2011
AD, atherogenic diet (12.5-40 % energy from fat, 0.075-1.5 % cholesterol, possibly with 0.5 % sodium
cholate); CCA, cholesterol/cholic acid–containing diet (1.25 % cholesterol and 0.5 % sodium cholate); CD,
cholesterol diet (normal chow with 0.5 % cholesterol); DM, diabetes mellitus; HCD, high-cholesterol diet
(20 % energy from fat, 0.15-1.25 % cholesterol); HFHC, high-fat/high-cholesterol diet (20 % fat, 1.25 %
cholesterol, and 0.5 % cholic acid); sRAGE, soluble receptor for AGEs; STZ, streptozotocin; TC, total
cholesterol; TG, triglycerides; WD, Western diet (Harlan Teklad TD96125 or TD88137). For the other
abbreviations, see text.
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Although STZ has been widely and quite reproducibly used in studies of diabetic
atherosclerosis, there are some drawbacks to its use. Firstly, STZ induces insulinopenic
diabetes, which in humans is not usually found in conjunction with severe
hypercholesterolemia. Secondly, STZ can produce non-specific toxic effects, especially if a
single high-dose injection is used, making it difficult to interpret if changes are caused by
hyperglycemia or by the toxin itself (Imaeda et al. 2002, Koulmanda et al. 2003, Palm et al.
2004, Inada et al. 2008). Thirdly, as noted previously, STZ diabetes evokes major changes in
plasma lipoproteins and leads to more extensive hyperlipidemia in most mouse strains,
making it difficult to examine the direct effects of hyperglycemia. The mechanism causing
increased lipid levels seems to be reduced catabolism of remnant lipoproteins – STZ diabetes
causes a defect in liver proteoglycans, which normally account for the trapping and rapid
clearance of apoB48 containing lipoproteins from the plasma (Ebara et al. 2000, Goldberg et
al. 2008). Here also diet selection plays a major role. A good example is the study of
Vikramadithyan et al. (2005), where STZ diabetes increased both lipid levels and
atherosclerosis when LDLR-/- mice were fed a high-fat diet. However, when lesion
development in heterozygous LDLR+/- mice with milder hyperlipidemia was induced with a
cholesterol/cholic acid-containing diet, hyperglycemia was able to accelerate atherosclerosis
in the absence of lipid changes. Furthermore, a cholic acid-containing high-fat diet elevated
cholesterol levels but nevertheless did not increase atherosclerosis in STZ-treated LDLR+/-
mice  with  or  without  CETP  expression  (Berti et al. 2005). In addition to these general
interpretation difficulties caused by different diets, cholate-containing diets are especially
problematic, since in addition to inducing hypercholesterolemia by promoting cholesterol
absorption and suppressing the conversion of cholesterol to bile acids, cholic acid has
pleiotrophic and even toxic effects e.g. triggering inflammation and interfering with liver
function and these may modify atherogenesis in ways not relevant to human disease.
Therefore its use in atherogenic diets is no longer recommended (Getz, Reardon 2006).
Since STZ is not optimal in the study of diabetic atherosclerosis, other strategies using a
chemical induction of T2D features have been implemented. One such approach is the
induction of central hyperphagia by a single i.p. injection of gold thioglucose (GTG), which
destroys the hypothalamic satiety center. As a result, mice develop significant obesity and
subsequently T2D-like perturbations in glucose metabolism (Karasawa, Takaishi &
Kumagae 2011). Lyngdorf et al. (2003) employed this strategy in ApoE-/- mice. Surprisingly,
despite the diabetic phenotype and slightly increased plasma cholesterol and TG levels,
GTG-treated ApoE-/- mice displayed significantly less atherosclerosis than control ApoE-/-
mice.
As a summary, chemical induction of diabetes has mostly relied on the use of STZ. It is a
well-established method for inducing T1D-like hyperglycemia and e.g. useful for
investigating the roles of certain genes (knock-out strategies) or studying the specific effects
of pharmacological agents. However, relevant control groups should always be included so
that the contribution of hyperglycemia versus lipids as well as the possible non-specific
effects of STZ to the end result can be controlled.
2.2.1.2 Atherosclerosis models with diet-induced diabetes
One very common way of developing mouse models with type 2 diabetic atherosclerosis is
by diet induction. Models generated by this approach are summarized in Table 4. With a
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Table 4. Atherosclerotic mouse models with diet-induced diabetes. The concept for the table was
obtained and adapted from Goldberg & Dansky (2006) and Wu & Huan (2007).
Mouse
model
Inducer DM
Hyper-
lipidemia
Athero-
sclerosis
Comments Reference
Diabetes does not affect atherosclerosis
C57Bl/6 DD
(6-14 wks)
2 TC­ (4.8 mM)
TG¯ (0.2 mM)
Fatty
streaks
Insulin ­, IR Schreyer,
1998
NOD PD
(18 wks)
1 TC­ (8.8 mM)
TG­ (1.3 mM)
None Cholate; hyperglycemia Keren,
2001
NOD WD
(18 wks)
1 TC­ (6.8 mM)
TG­ (2.8 mM)
None Hyperglycemia Keren,
2001
ApoE-/- DD
(16 wks)
2 TC« (10.2 mM)
TG« (0.6 mM)
« No effect on glucose
metabolism
Schreyer,
2003
LDLR-/- HFD
(20 wks)
2 TC­ (18.2 mM)
TG¯ (2.8 mM)
« Glucose ­, insulin ­, IR Wu, 2006
LDLR-/-hAR HFD
(20 wks)
2 Similar as
above
« Similar as above Wu, 2006
Diabetes affects atherosclerosis and alters plasma lipid levels
LDLR-/- WD
(17 wks)
2 TC­ (27.0 mM)
TG­ (4.3 mM)
­ Glucose ­, insulin ­,
vs. HFD w/o cholesterol +
similar dysglycemia:
lesions ­
Towler,
1998
LDLR-/- WD
(4.5 mos)
2 TC­ (25.0 mM)
TG­ (2.6 mM)
­ Insulin ­, IR;
vs. fructose diet w/ equal
cholesterol + euglycemia:
lesions «
Merat,
1999
LDLR-/- DD
(16 wks)
2 TC­ (17.9 mM)
TG­ (5.0 mM)
­ Glucose ­, insulin ­, IR Schreyer,
2003
ApoE-/- WD
(5 wks)
2 TC­ (33.8 mM)
TG­ (1.1 mM)
NI ­ Glucose ­, insulin ­ Phillips,
2003
ApoE*Leiden HCD
(28 wks)
2 TC­ (20 mM)
TG­ (1.7 mM)
­ IR Zadelaar,
2006
HuB HFD
(12 mos)
2 TC­ (3.5 mM)
TG­ (1.0 mM)
Fatty
streaks
Glucose ­, insulin ­, IR Bartels,
2009
Diabetes affects atherosclerosis without changes in plasma lipids
ApoE-/- HFD
(17 wks)
2 TC« (15.6 mM)
TG« (1.1 mM)
­ Glucose ­, IR vs. mice w/
equal lipids
King, 2010
Other potential models
L-PGDS-/- HFD
(20 wks)
2 - ­ x 5 Nephropathy Ragolia,
2005
DD, diabetogenic diet (Bioserve F1850: 35.5 % energy from fat); DM, diabetes mellitus; HCD, high-
cholesterol diet (20 % energy from fat, 0.15-1.25 % cholesterol); HFD, high-fat diet (20-60 % energy from
fat, usually no cholesterol); NI, neointima; PD, Paigen diet (1.25 % cholesterol, 0.5 % sodium cholate); TC,
total cholesterol; TG, triglycerides; WD, Western diet (Harlan Teklad TD96125 or TD88137). For the other
abbreviations, see text.
dietary induction of diabetes, results depend greatly on the diet composition: some diets
induce obesity and IR, whereas others cause mostly hyperlipidemia without major
alterations in glucose metabolism. For example, the high-fat Western diet elevates plasma
cholesterol more than high-fat diets rich in carbohydrates, and this per se can affect lesion
development (Temel, Rudel 2007). There is also extensive variation in the effects between
different mouse strains and genetic models. C57BL/6 mice are the most atherosclerosis
sensitive strain, but seem to be quite resistant to diabetes-accelerated atherosclerosis
(Schreyer, Wilson & LeBoeuf 1998). The so-called diabetogenic diet induces obesity, mild
diabetic phenotype, profound hyperlipidemia and increased atherosclerosis in LDLR+/- mice,
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whereas ApoE-/- mice are resistant to changes other than obesity (Schreyer et al. 2002,
Schreyer et al. 2003). In addition, when fed a Western diet, the effect on glucose metabolism
is  more  marked  in  LDLR-/- mice  (Towler et al. 1998, Merat et al. 1999, Karagiannides et al.
2008) than in ApoE-/- mice, which only develop profound hyperlipidemia but are mainly
protected against the diabetic effects (Karagiannides et al. 2008, Phillips et al. 2003, Su et al.
2006). Overall, the diabetic features induced by diet are so subtle that it is likely that the
increases noted in atherosclerosis are a consequence of the hyperlipidemia rather than to
alterations in glucose metabolism. Consistently, in the study of Wu et al. (2006) the
expression of hAR that aggravated the effects of STZ-induced hyperglycemia
(Vikramadithyan et al. 2005) had no effect in a milder diabetic phenotype induced by diet.
In the same study, diet-induced diabetic features did not affect lesions in LDLR-/- mice when
compared to euglycemic LDLR-/- mice with equal lipid levels, supporting the superior effect
of hyperlipidemia. Only when ApoE-/- mice were fed an extremely high-fat diet without
cholesterol, glucose intolerance and increased lesion formation without significant elevation
in total cholesterol occurred (King et al. 2010).
Aside from inducing diabetes in hyperlipidemic models, Ragolia et al. (2005) investigated
prostaglandin D2 synthase (L-PGDS) knock-out mice. These mice became insulin resistant on
diabetogenic diet and developed more atherosclerosis compared to both C57Bl/6 controls
and insulin sensitive L-PGDS-/- mice. However, the impact of IR remains elusive, since
plasma lipid values were not reported. In non-obese diabetic (NOD) mice, a spontaneous
model of T1D, high-fat diets with and without cholate have been used in an attempt to
induce atherosclerosis (Keren et al. 2001). Although modest increases in lipid levels were
attained in hyperglycemic versus normoglycemic animals, no lesion formation was observed.
This reflects the genetically predetermined resistance to atherosclerosis in some strains and
underlines the importance of background strain selection and genetic modification if
atherosclerosis is to be studied in mice.
In  conclusion,  inducing  diabetic  traits  by  diet  is  a  common method,  although it  usually
results in a rather mild diabetic phenotype, which in most cases does not appear to affect
atherosclerosis without concomitantly raised plasma lipid levels. In addition, notable
variance in diet compositions and durations complicate direct comparisons of studies.
2.2.1.3 Genetic models of diabetic atherosclerosis
Attempts to model diabetic macrovascular disease by modifying genes involved in
carbohydrate and/or lipid metabolism have produced numerous genetically modified
mouse models (summarized in Table 5). In order to avoid the disadvantages of STZ, Renard
et al. (2004) studied the effects of T1D on atherosclerosis in LDLR−/− mice expressing a viral
glycoprotein (GP) under the insulin promoter (LDLR−/−GP mouse). In these mice, T1D can be
induced by lymphocytic choriomeningitis virus infection, which causes an autoimmune-
mediated destruction of b-cells. When fed a cholesterol-free diet, LDLR−/−GP mice  did  not
develop diabetes-induced lipid abnormalities but nonetheless showed an increased lesion
area. However, on cholesterol-rich diets diabetes aggravated hyperlipidemia and led to
increased lesion amount. This suggested that in a setting of moderate hyperlipidemia
(produced  by  the  LDLR−/− background) hyperglycemia was likely to stimulate lesion
initiation, whereas it is mainly the secondary lipid abnormalities that contribute to the
progression of lesions. This was subsequently confirmed by Johansson et al. (2008), who
observed that the vulnerable plaque phenotype found in LDLR−/−GP mice was abolished
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with a reduction of secondary hypertriglyceridemia. A model of spontaneous T1D, the Akita
mouse (Ins2Akita) (Yoshioka et al. 1997, Wang et al. 1999), has also been utilized in
atherosclerosis studies. In these mice, apoptosis of b-cells is caused by ER stress following
the improper folding of proinsulin (Yoshinaga et al. 2005). Recently, the Akita mice have
been crossed with both LDLR-/- (Zhou et al. 2011) and ApoE-/- mice (Jun, Ma & Segar 2011). In
both backgrounds, diabetes increased atherosclerosis with accompanying elevations in lipid
levels, probably by altering the hepatic expression of genes regulating lipid homeostasis.
Although not optimal, these genetic models provide better and more relevant tools for
studying T1D-related macrovascular complications than the use of STZ.
Although hyperglycemia as such is a strong risk factor for diabetic vascular
complications, additional factors contribute especially to the development of diabetic
macrovascular diseases. Thus, it would be essential to achieve models representing the
overall risk profile combining diabetic metabolic changes and atherosclerosis. To date, this
has mostly been pursued by cross-breeding leptin-deficient (ob/ob) or leptin
receptor–deficient (db/db) mice with atherosclerotic ApoE-/- (Wu et al. 2005, Gruen et al. 2006,
Wendt et al. 2006) and LDLR-/- mice (Gruen et al. 2006, Wendt et al. 2006, Hasty et al. 2001).
Recently the ob/ob mouse was cross-bred also with ApoE-/-ApoB100/100 and LDLR-/-ApoB100/100
mice (Lloyd et al. 2008), resulting in promising models of the metabolic syndrome. However,
also in these models, the major shortcoming is that diabetes does not appear to affect
atherosclerosis without large concomitant changes in plasma lipid levels (Goldberg, Dansky
2006, Kennedy et al. 2010). In fact, when compared to hyperlipidemic controls with similar
cholesterol leves, leptin deficiency can actually protect from atherosclerosis in both LDLR-/-
(Taleb et al. 2007) and ApoE-/- backgrounds (Chiba et al. 2008).
The effects of obesity-induced IR on atherosclerosis have been studied also in other
models of obesity. When LDLR-/- mice  were  crossed  with  yellow  agouti  (Ay/a)  mice,  a
spontaneous model of adult-onset obesity (Coenen, Hasty 2007), no increase in lesion
formation was seen despite significant obesity, IR, and elevated cholesterol and TG levels
compared to the respective LDLR-/- controls. A similar study was also carried out in ApoE-/-
mice (Gao et al. 2007). Unexpectedly, the lack of apoE totally prevented the development of
obesity and glucose intolerance, implicating the involvement of apoE in the pathogenesis of
obesity and related disorders.
Other approaches include crossing the ApoE-/- mice  with  type  2  diabetic  MKR-mice
overexpressing a dominant negative insulin-like growth factor-I receptor in skeletal muscle
(Kawashima et al. 2009). In this model, apoE deficiency surprisingly abrogated diabetic traits
but nevertheless caused no reduction in atherosclerosis. This was likely due to the elevated
cholesterol levels present in ApoE-/-MKR  mice  compared  to  ApoE-/- mice, once again
emphasizing the dominance of hypercholesterolemia in mouse atherogenesis. However,
there are also genetic models without diabetes-induced lipid elevations. The role of IR in
atherogenesis has been studied in ApoE-/- mice with a partial (Gonzalez-Navarro et al. 2008,
Clough et al. 2005) or total deficiency of insulin receptor substrate 2 (IRS2) (Baumgartl et al.
2006, Gonzalez-Navarro et al. 2007). These mice do not exhibit a diabetic phenotype on
normal diet but systemic IR is provoked by high-fat diet, accompanied with increased aortic
lesion development when compared to ApoE-/- mice with similar plasma lipid levels. Since
the plasma lipid levels of these diabetic mice resemble those of the respective
hyperlipidemic background, it is possible to study and differentiate mechanisms behind the
observed proatherogenic effects.
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In short, genetic modification is the most potent way of achieving mouse models
mimicking the overall metabolic disorders typically found in an average cardiovascular
patient.
Table 5. Atherosclerotic mouse models with genetically induced diabetes. The conceptual idea for
the table was obtained from Goldberg & Dansky (2006) and Wu & Huan (2007).
Mouse model Diet DM
Hyper-
lipidemia
Athero-
sclerosis
Comments Reference
Diabetes does not increase atherosclerosis
LDLR–/–Ay/a WD
(12 wks)
2 TC­ (38.9 mM)
TG­ (9.2 mM)
« Insulin ­ Coenen,
2007
LDLR–/–ob/ob 2 TC« (50.0 mM)
TG­ (15.0 mM)
¯ Vs. LDLR–/– mice
w/ equal TC
(HCD)
Taleb, 2007
ApoE-/-ob/ob AD
(16 wks)
2 TC« (67.5 mM)
TG­ (1.0 mM)
¯ 50 % ± cholate Chiba, 2008
ApoE-/-IRS2+/- 2 TC« (6.5 mM)
TG« (1.5 mM)
« Gonzáles-
Navarro,
2008
ApoE-/-MKR HCD
(16 wks)
2 TC­ (95 mM)
TG­ (2500 nM)
« IR ¯ vs. MKR Kawashima,
2009
Diabetes affects atherosclerosis and alters plasma lipid levels
LDLR-/-ob/ob 2 TC­ (44.5 mM)
TG­ (11.5 mM)
­ Hasty, 2001
LDLR-/-GP AD
(12 wks)
1 TC­ (34.9 mM)
TG­ (23.8mM)
­ x 2 Lesion
hemorrhages ­
Renard,
2004
LDLR-/-GP HFD
(16 wks
prior to
DM)
1 TC« (15 mM)
TG­ (3.5 mM)
« Intraplaque
hemorrhage ­,
plaque
disruption ­
Johansson,
2008
LDLR-/-ob/ob 2 TC­ (17.2 mM)
TG­ (3.4 mM)
­ x 4 Gruen,
2006
LDLR-/-ApoB100/100ob/ob 2 TC­ (44.8 mM)
TG­ (7.4 mM)
­ Vs. C57Bl/6:
Insulin ­, BP ­
Lloyd, 2008
ApoE-/-db/db 2 TC­ (15.1 mM)
TG­ (2.6 mM)
­ x 3 Wu, 2005
ApoE-/-db/db WD
(10 wks)
2 TC­ (37.9 mM)
TG­ (10.1 mM)
­ Wu, 2005
ApoE-/-db/db 2 TC­ (24.8 mM)
TG« (0.2 mM)
­ x 3 Wendt,
2006
ApoE-/-ob/ob 2 TC­ (17.7 mM)
TG« (1.5 mM)
­ x 3 Gruen,
2006
ApoE-/-ApoB100/100ob/ob 2 TC­ (31.2 mM)
TG­ (3.8 mM)
­ Vs. C57Bl/6:
glucose ­,
insulin ­, IR,
BP ­
Lloyd, 2008
LDLR-/-Ins2Akita HCD
(16 wks)
1 TC­ (32.5 mM)
TG­ (5.3 mM)
­ x 2 Phenotype
stronger
in males
Zhou, 2011
ApoE-/-Ins2Akita 1 TC­ (22.5 mM)
TG­ (0.9 mM)
­ x 3 Jun, 2011
Diabetes affects atherosclerosis without changes in plasma lipids
LDLR-/-GP 1 TC« (8.8 mM)
TG« (2.1 mM)
­ x 3 Renard,
2004
ApoE-/-IRS2-/- WD (9-
12 wks)
2 TC« (64.9 mM)
TG« (0.8 mM)
­ Baumgartl,
2006
ApoE-/-IRS2-/- AD
(4 wks)
2 TC« (15.6 mM) ­ Gonzáles-
Navarro,
2007
AD, atherogenic diet (10.8-40 % energy from fat, 0.075-1.5 % cholesterol, possibly with 0.5 % sodium
cholate); BP, blood pressure; DM, diabetes mellitus; HCD, high-cholesterol diet (20 % energy from fat,
0.15-1.25 % cholesterol); HFD, high-fat diet (20-60 % energy from fat, usually no cholesterol); TC, total
cholesterol; TG, triglycerides; WD, Western diet (Harlan Teklad TD96125 or TD88137). For the other
abbreviations, see text.
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2.2.2 Mouse models of other macrovascular complications in diabetes
In addition to general atherosclerosis, macrovascular complications in models of diabetic
atherosclerosis have been studied to a lesser extent. CAD and/or myocardial infarction have
been examined in hypercholesterolemic models (Calara et al. 2001, Nakashima et al. 1994,
Chase et al. 2007, Coleman et al. 2006, Dworschak et al. 2005, Kuhlencordt et al. 2001, Caligiuri
et al. 1999, Li et al. 2001, Saraste et al. 2008), but data from the diabetic conditions is lacking.
There is also little information available on peripheral arterial disease. Recently,
therapeutical angiogenesis was studied in ApoE-/- mice with STZ-induced hyperglycemia
(Balestrieri et al. 2010). It was found that hyperglycemia impaired the capillarization and
perfusion of the ischemic hindlimbs. However, the impact of increased lipid levels in
diabetic versus non-diabetic ApoE-/- mice must be taken into consideration before one can
draw conclusions about the worsened ischemic response. In fact, when arteriogenesis in an
ischemic  hindlimb  was  compared  in  mouse  models  of  T1D  (STZ-induction  and  the  NOD
mice), IR (ob/ob) and hypercholesterolemia (APOE*Leiden mouse), hypercholesterolemia
reduced collateral arterial growth significantly more than hyperglycemia or IR alone (van
Weel et al. 2006), which is uniformly in line with the abovementioned observations from
general atherosclerosis.
Because of the natural resistance of mice to atherosclerosis, diabetic mouse models
provide a convenient tool for studying diabetic cardiomyopathy. The models of T1D present
varying phenotypes with left ventricular diastolic dysfunction being the dominant feature in
the Akita mice (Basu et al. 2009), whereas also systolic dysfunction is represented in OVE26
(Xie et al. 2011), NOD (Pacher et al. 2002) and STZ treated mice (reviewed in (Poornima,
Parikh & Shannon 2006, Hsueh et al. 2007). Based on the cardiac phenotypes of these models,
it seems that hyperglycemia and the absence of insulin are sufficient to cause functional
defects but the structural changes of DCM might not be duplicated. In contrast to humans,
where the clinical picture of DCM is similar in T1D and T2D, the cardiac phenotypes of T2D
mouse  models  differs  from T1D models  in  that  systolic  function  is  usually  preserved.  The
most  common  finding  in  ob/ob  and  db/db  mice  is  cardiac  hypertrophy,  with  contractile
disturbances and increased chamber stiffness seen in some cases (Poornima, Parikh &
Shannon 2006).
2.2.3 Mouse models of diabetic microvascular complications
The studies and model development of diabetic retinopathy in mice have thus far limited to
a few strains. Many models, such as STZ diabetic C57Bl/6 mice (Feit-Leichman et al. 2005),
the Akita mice (Barber et al. 2005, Gastinger et al. 2008) and db/db mice (Cheung et al. 2005)
develop vascular and neural changes typical of the early stages of diabetic retinopathy over
a period of 6-9 months of diabetes. Despite the fact that the db/db mice with a ApoE-/-
background display a more pronounced retinal phenotype (Barile et al. 2005), profound
retinopathy with capillary and neuronal loss, capillary obliteration, retinal edema and
preretinal neovascularization are absent in most models. Recently, Akita mice were crossed
with Kimba mice, which transiently overexpress human VEGF in their photoreceptors
(Rakoczy et al. 2010). In this “Akimba” mouse, the combination of hyperglycemia and
short-term elevation in VEGF expression results in a more severe retinal pathology with also
retinal neovascularization and persistent retinal edema. Although etiologically not identical
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to the human disease, at present the Akimba mice are the only model displaying the more
advanced stages of diabetic retinopathy.
The validation criteria for an ideal murine models of diabetic nephropathy suggested by
the AMDCC are as follows: 1) over 50 % decline in glomerular filtration rate, 2) over 10-fold
increase in albuminuria compared to controls, 3) mesangial matrix expansion, 4) arterial
hyalinosis, 5) glomerular basement membrane thickening by >50 %, and 6) tubulointerstitial
fibrosis (Brosius et al. 2009). Despite the fact that no model currently fulfills all of these
criteria, many mouse models demonstrate a varying degree of characteristics resembling
human diabetic nephropathy (Breyer et al. 2005). Although extensively used as a T1D model,
STZ induced hyperglycemia induces only modest renal changes: mild increase in
albuminuria and serum creatinine, as well as faint histopathological lesions (Tesch, Allen
2007). A stronger phenotype is seen in STZ diabetic ApoE-/- mice displaying albuminuria and
glomerular and tubulointerstitial injury (Lassila et al. 2004), suggesting a contributory role
for hyperlipidemia in the progression of diabetic renal disease. This approach has been
widely used in different settings, e.g. with different genetic modifications such as the
ApoE-/-GPx1-/-  mice, which showed further accelerated renal pathology (Chew et al. 2010). In
type 2 diabetic nephropathy studies, the rapid onset of renal injury has made the db/db
mouse a common model of choice (Tesch, Lim 2011). The nephropathic phenotype of db/db
mice can be accelerated by removing one kidney or by genetic modification, e.g. deleting
endothelial nitric oxide synthase (Zhao et al. 2006).
In order to properly mimic human diabetic neuropathy, experimental models should
demonstrate the following key features: 1) sensory loss (analyzed by thermal sensitivity
assessment), 2) electrophysically measured nerve impairment (nerve conduction
measurement), and 3) nerve fiber loss (nerve fiber density) (Sullivan et al. 2007). Despite
profound and persistent hyperglycemia, STZ-induced diabetes does not produce
neuropathic disorders. In the Akita mouse, the phenotype is also mild. In fact, it has been
noted that the genetic background is an important factor determining the susceptibility to
diabetic nephropathy with the common C57Bl/6 strain being relatively resistant.
Consistently,  the  most  robust  model  of  diabetic  neuropathy  is  the  db/db  mouse  (with  its
typical C57BKLS background) exhibiting an impaired response in all areas. (Sullivan et al.
2007).
2.3 ADVANCED THERAPIES FOR DIABETIC CARDIOVASCULAR
COMPLICATIONS
Since the causes underlying the increased risk for CVD in diabetes are multifactorial,
therapeutic interventions addressing each risk factor are needed. The benefits of nutritional
and lifestyle guidance cannot be understated as significant non-pharmacological treatments
in the primary prevention of CVD endpoints, and have been emphasized also in practice
guidelines. Weight control by reducing the proportion of fat to ~30 % of daily energy, the
preference of unsaturated fatty acids, and adequate fiber intake form the basis for nutritional
management. Together with physical activity and the cessation of smoking, these changes
profoundly reduce the risk of CVD in diabetic patients (Rydén et al. 2007, Buse et al. 2007).
The pharmacological management of CVD in diabetes consists of controlling blood
glucose, lipid alterations, hypertension and achieving the prevention of thrombosis. The
choice of glucose-lowering therapy is tailored individually. In T2D, oral antidiabetics are the
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primary strategy before resorting to insulin replacement therapy. These drugs can be used
for stimulating insulin secretion (sulphonylureas, glinides and gliptins), increasing insulin
sensitivity in peripheral tissues (glitazones), reducing hepatic gluconeogenesis (biguanides),
and slowing the digestion of carbohydrates (alpha-glucosidase inhibitors). The latest
entrants are injectable incretin mimetics that increase insulin release and, unlike most other
anti-diabetic agents, induce moderate weight loss by delaying gastric emptying and
reducing food intake. For the treatment of dyslipidemia, lowering of LDL cholesterol levels
with statins is the main intervention in both the primary and secondary prevention of CVD
endpoints. The blood pressure recommendation in diabetes is <130/80 mmHg and usually
this can only be achieved by a combination of several anti-hypertensive drugs. Inhibitors of
the renin-angiotensin system (i.e. angiotensin-converting enzyme inhibitors and angiotensin
receptor blockers) should always be included in the treatment, since they have been shown
to be most effective in reducing CVD events and the progression of renal changes in diabetic
patients. Despite the current uncertainty of the effect of the antithrombotic agent aspirin
(acetylsalicylic acid) on the prevention of CVD events in diabetes, all current guidelines
recommend the regular use of low dose aspirin (~100 mg/day). (Rydén et al. 2007, Buse et al.
2007, Pignone et al. 2010).
Alongside traditional pharmacology, the increasing knowledge of the molecular
background and mechanisms of diseases gives rise to new opportunities for more targeted
medical treatments. New therapeutic approaches are emerging in parallel to conventional
small-molecule pharmaceuticals - since the year 2000 about one quarter of all genuinely new
drugs approved have been biopharmaceuticals (Walsh 2010) and undoubtedly their share of
products in the pipeline of pharmaceutical companies is even much higher.
Biopharmaceuticals are medicinal products whose active substance is made by or derived
from  a  living  organism  and  they  include  vaccines,  blood  products,  allergens,  recombinant
therapeutic proteins and the so-called advanced therapies: gene therapy, tissue engineered
products and somatic cell therapy.
2.3.1 Gene therapy
Gene therapy is defined as a medicinal product whose prophylactic, diagnostic or
therapeutic effects directly relate to the transferred genetic material itself or to the
expression product of this genetic material (Directive 2001/83/EC part IV, revised Annex I).
In practice, gene transfer is performed into somatic cells either removed from the body
(ex vivo approach) or directly into cells in their normal location (in vivo approach) with an
expression system containing the genetic material and a vector of viral or non-viral origin.
When aiming at a therapeutic effect, the transgene can function by regulating, repairing,
replacing, adding or deleting a genetic sequence in the transduced cell. For example, the
transduced cell can be induced to produce the desired therapeutical protein or, on the
contrary, the expression of a harmful or faulty protein can be prevented. The ideal gene
transfer vector would exhibit low immunogenicity, have an acceptable safety profile, a high
transduction efficacy and display expression of the transgene for a defined time period
(Gupta, Tongers & Losordo 2009). Although non-viral vectors, such as plasmid DNA,
possess a rather optimal safety profile, they also have very low efficacy. Therefore viral
vectors with a naturally high gene transfer efficiency are preferred and have so far been
used in ~70 % of gene therapy clinical trials (Journal of Gene Medicine,
http://www.wiley.com/legacy/wileychi/ genmed/clinical/) (Young et al. 2006). Adenovirus
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with a highly efficient transduction of both proliferating and non-proliferating cells and a
transient expression of the therapeutic gene, has been the most used viral vector.
Retroviruses (mostly originating from murine leukemia virus) transduce only proliferating
cells and integrate into the host genome, inducing a permanent expression of the transgene
but also causing the risk of activating unwanted genes, e.g. oncogenes, through insertional
mutagenesis. Therefore, for therapeutic applications requiring long-term gene expression,
vectors with a more favourable safety profile such as adeno-associated virus (AAV) and
lentivirus are being developed. Overall, different viruses vary greatly in their characteristics,
e.g. tropism, immunogenicity, transgene capacity and integration, and the duration of
transgene expression. Thus the optimal vector needs to be chosen based on the given
application.
Compared to traditional pharmacology, the major advantages of gene therapy are 1) the
possibility of targeting the treatment only to selected tissues or cell types thus reducing
systemic toxicity, and 2) the prospect of achieving a long treatment effect with a single
administration. Applications of gene therapy have in the last 20 years broadened from
monogenic diseases (e.g. severe immunodeficiencies) to the treatment of multifactorial
acquired diseases. Since the first gene transfer made to a human being took place in 1989
(Rosenberg et al. 1990), over 1700 clinical trials of gene therapy have been conducted or are
underway (http://www.wiley.com/legacy/wileychi/genmed/clinical/). A substantial propor-
tion (65 % of all trials) has been cancer related, with CVD, monogenic disorders and
infectious diseases each accounting for about 8 % of trials. However, so far no nucleic acid-
based drug has been approved for clinical use in either Europe or the United States. Only in
China are two products on the market for treating head and neck squamous cell carcinoma:
Gendicine™ is based on an adenoviral transfer of the tumor suppressor gene p53, and
Oncorine™ is an oncolytic adenovirus promoting the lysis of malignant cells. Two products
that have been closest to marketing authorization approval in the Western world are the
Dutch Glybera® for LPL deficiency and Anglo-Finnish Cerepro® for the treatment of
malignant glioma. Glybera® is based on AAV carrying a variant of the human LPL gene.
Cerepro® therapy contains adenoviral gene transfer of thymidine kinase, which when
combined with ganciclovir medication induces the death of dividing tumor cells. However,
only Cerepro® is currently in clinical use, since it has received a named patient permission
in Finland and France.
2.3.1.1 Cardiovascular gene therapy
Many components of CVD are successfully managed with traditional pharmacotherapy,
whereas in the treatment of fatal complications, these are usually not sufficient and
revascularization procedures are needed. However, many patients are not candidates for
conventional therapeutic modalities e.g. because of a diffuse disease or comorbidities, and a
considerable proportion of those treated experience incomplete revascularization. Thus
several gene therapy approaches have been designed with the most explored being the
induction of therapeutic angiogenesis, the prevention of restenosis after angioplasty and in
vein grafts, as well as the treatment of heart failure (Rissanen, Ylä-Herttuala 2007).
Therapeutic angiogenesis, i.e. the induction of therapeutic vascular growth, represents the
most extensively studied approach in cardiovascular gene therapy and constitutes the
majority of clinical trials performed so far. The aim is to increase perfusion in ischemic tissue
by promoting the formation of supplemental collaterals for bypassing an occluded artery. In
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preclinical studies performed in animal models of myocardial or hindlimb ischemia, several
factors have been shown to induce angiogenesis (Rissanen, Ylä-Herttuala 2007). VEGF-A has
demonstrated the highest angiogenic potency in experimental studies and therefore has
been the main focus also in clinical trials ever since the first human patient with critical limb
ischemia was treated in 1996 (Isner et al. 1996). Phase I studies have shown promising results
in treating both peripheral and CAD (Ylä-Herttuala et al. 2007). The later stages of trials with
controls and randomization have so far produced disappointing results in terms of efficacy,
indicating the need for further optimization, although the experiences from approximately
2500 patients of placebo-controlled studies have proven angiogenic gene therapy to be safe
and feasible (Zachary, Morgan 2011). Nevertheless, concerns about the role of VEGF-A in
atherogenesis have been raised since there is much evidence for an association between
neovascularization and the severity of atherosclerotic disease (Moreno et al. 2006). Studies in
experimental animals have produced confusing and even conflicting data (Zachary, Morgan
2011), and thus the issue remains contentious and of high importance.
The non-angiogenic gene therapy of CVD includes the prevention of post-angioplasty
restenosis and stenosis of the vein grafts used in by-pass surgery. Drug-eluting stents are
currently the treatment of choice to alleviate balloon-angioplasty restenosis, but gene
therapy approaches could enhance their benefits by introducing factors improving
re-endothelialization and endothelial function. Vein grafts, on the other hand, offer a feasible
option for ex vivo gene transfers, and pre-clinical studies introducing vasculoprotective
factors inhibiting thrombosis, vasoconstriction, oxidative stress, inflammation and intimal
thickening have been conducted (Rissanen, Ylä-Herttuala 2007). In addition to the
vasculature, gene therapy has been targeted to cardiomyocytes to improve cardiac function
and prevent heart failure. The enhancement of calcium metabolism to improve contractility,
and targeting the myocardial β-adrenergic system to modulate electrical activity and prevent
arrhythmias, have been the most extensively studied approaches (Rissanen, Ylä-Herttuala
2007, Njeim, Hajjar 2010). The concept of a biological pacemaker has also gathered interest
(Cho, Marban 2010).
2.3.1.1.1 Angiogenic gene therapy in diabetes
Despite promising preclinical studies, angiogenic gene therapy has so far shown limited
efficacy in clinical trials. One explanation might be the differences between human patient
populations and the animals used in preclinical research. Since virtually all patients needing
revascularization procedures are suffering from a variety of antiangiogenic problems, such
as endothelial dysfunction, hypercholesterolemia and diabetes, it is not surprising that the
response to treatment is not the same as in healthy, young animals that are usually used in
the preclinical testing. This brings about awareness of both the need for modification of the
therapeutic strategy (e.g. improving the effect of angiogenic agent by combined amelioration
of the endothelial dysfunction) and the importance of animal model selection. (Boodhwani,
Sellke 2009).
In addition to creating a challenging environment for successful angiogenic interventions,
the fact that both excessive and insufficient angiogenesis contribute to different diabetic
vascular complications, calls for further considerations in relation to the safety of pro- and
anti-angiogenic gene therapy. In theory, systemic effects could worsen some other diabetic
vascular complication outside the target tissue. One example can be seen in the use of
systemically administered anti-VEGF antibodies and VEGF receptor inhibitors in cancer
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treatment, where adverse cardiovascular effects such as hypertension and thromboembolic
events are commonly encountered (Force, Kerkelä 2008). However, the protocols of
pro-angiogenic gene therapy used in clinical trials typically include rather localized dosage
with either intramuscular or intra-arterial administration near to the target site.
Anti-angiogenic therapy for diabetic retinopathy can also be performed with local
intravitreal injections and thus contain very little risk for systemic effects. (Duh, Aiello 1999).
Nevertheless, the role of angiogenesis in the development of vulnerable atherosclerotic
plaques remains a subject of debate and the controversial results emerging from animal
studies warrant further investigations (Khurana et al. 2005).
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3 Aims of the study
The aim of this thesis was to evaluate the impact and safety of VEGF gene therapy in
relation to atherosclerosis and to develop a new mouse model for studying the
cardiovascular complications related to type 2 diabetes.
The specific aims were as follows:
I To investigate adenoviral VEGF gene therapy with regard to its effect on atherosclerotic
lesion development in a mouse model of hypercholesterolemia.
II To establish and characterize a new mouse model for type 2 diabetes and cardiovascular
diseases.
III To study the status of coronary artery disease and cardiac function in mice manifesting
atherosclerosis and type 2 diabetes.
IV To characterize the ocular phenotype of the established mouse model of type 2 diabetes
and atherosclerosis.
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4 Materials and methods
4.1 ANIMALS
Hypercholesterolemic LDLR-/-ApoB100/100 mice (Véniant et al. 1998) (studies I-IV) in a mixed
genetic background ( 75 % C57BL/6J and 25 % 129/SvJae) were originally obtained from
the Jackson Laboratory (stock no 003000; Bar Harbor, Maine, USA). The model was modified
to manifest atherosclerosis with the characteristics of T2D by crossbreeding them for ten
generations with C57BL6/SJL mice overexpressing insulin-like growth factor II (IGF-II) in
pancreatic β-cells (Devedjian et al. 2000) (study II). The resulting
IGF-II/LDLR-/-ApoB100/100 mice were then characterized in studies II-IV and IGF-II negative
LDLR-/-ApoB100/100 littermates (II-IV), IGF-II mice (II) and C57Bl/6J mice (III) served as
controls. The used mouse strains and diets are outlined in Table 6.
Table 6. Characteristics of the study groups.
Study Mouse strains Diet groups Age of mice
I LDLR-/-ApoB100/100 Western diet (3 months) 5 and 8 months
II LDLR-/-ApoB100/100
IGF-II/LDLR-/-ApoB100/100
IGF-II
Chow diet
Western diet (3 months)
6 months
15 months
III LDLR-/-ApoB100/100
IGF-II/LDLR-/-ApoB100/100
C57Bl/6J
Western diet (3 months) 18 months
IV LDLR-/-ApoB100/100
IGF-II/LDLR-/-ApoB100/100
C57Bl/6J
Chow diet
Western diet (3 months)
3 months
15 months
Mice were fed ad libitum a normal chow diet (R36, Lactamin, Stockholm, Sweden) either
throughout the study (II, IV) or were put on a high-fat Western diet (TD 88137, Harlan
Teklad: 42 % of calories from fat and 0.15 % from cholesterol, no sodium cholate) for three
(I-IV) or 5.5 months (I) before analyses Both female and male mice were used in all studies.
The following anesthetics were used: a combination of fentanyl-fluanisone (3.15 and 10
mg/kg; Hypnorm®, Janssen) and midazolam (5 mg/kg; Dormicum®, Roche) s.c. (study I and
for GTT in studies II-IV), or xylazine (10mg/kg; Rompun®, Bayer) and ketamine (80mg/kg;
Ketalar®, Pfizer) s.c. (II-IV). In echocardiography and ultrasonography (III) inhalation
anesthesia with isoflurane was used (induction: 4.5 % isoflurane, 450 ml air, maintenance:
2.0 % isoflurane, 200 ml air, Baxter International Inc., Deerfield, IL, USA). Mice were housed
in groups and maintained in a temperature- and humidity-controlled environment with a
12-hour light/dark cycle at the National Laboratory Animal Centre in Kuopio. Euthanasia
was performed with carbon dioxide. Experiments were approved by the Experimental
Animal Committee of the University of Kuopio and the National Experimental Animal
Board.
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4.2 GENE TRANSFERS
First generation replication-deficient adenoviruses were used as gene transfer vectors.
Systemic gene transfers via the tail vein were performed in anesthetized animals with
adenoviruses encoding human VEGF-A165, VEGF-B167, VEGF-C or VEGF-DΔNΔC under CMV
promoter (I). A viral dose of 1x109 plaque forming units (pfu) in a total injection volume of
200 µl was used. Saline, recombinant human VEGF-A protein (rhVEGF-A, 2 µg/kg) and
adenovirus encoding β-galactosidase (LacZ) under CMV promoter were used as controls.
The functionality of the adenoviruses had been tested previously (Bhardwaj et al. 2003,
Rissanen et al. 2003). Mice were consuming a Western diet before the gene transfer for either
6 or 16 weeks, and were sacrificed 6 weeks after the gene transfer.
4.3 METABOLIC ANALYSES AND CLINICAL CHEMISTRY
The analyses of glucose metabolism included blood glucose measurement in fed and
overnight fasted animals (II-IV), intraperitoneal glucose tolerance test (GTT) (II-IV) and
insulin tolerance tests (ITT) (II). GTT was performed in mice fasted overnight (15 h).
Anesthetized animals received an intraperitoneal glucose injection (1.5 g/kg) and blood
glucose was measured from the tail vein immediately before the injection and at time-points
30, 60, 90 and 120 min. For insulin tolerance tests (ITT) mice were fasted for 5 hours,
anesthetized, injected i.p. with a solution of insulin (0.5 IU/kg; Ultratard®, Novo Nordisk
A/S) and blood glucose was measured at baseline and 5, 15, 30, 45 and 60 min post-injection.
Blood glucose determination was performed with Ascensia Elite XL glucometer (Bayer).
Plasma insulin levels were measured using a kit based on enzyme-linked immunoassay
(ELISA) (Linco Research Inc., Missouri, USA) (II).
The assessment of plasma lipids was done from samples after overnight fasting.
Triglycerides were determined enzymatically using GPO-PAP (Ecoline® S+, Diasys,
Diagnostic Systems Gmbh, Holzheim, Germany) (I-IV). The quantification of total
cholesterol was performed with CHOD-PAP kit (Ecoline® 25, Merck KgaA, Darmstadt,
Germany) (I-IV). Free fatty acids were measured by the acyl-CoA synthase and acyl-CoA
oxidase method (Wako Chemicals GmbH, Neuss, Germany) (II). Plasma lipoprotein profiles
were investigated by fractionating fasting plasma samples (200 µl) with fast-performance
liquid chromatography (Yan et al. 2007).
The measurements of plasma cytokine concentrations were done with ELISA assays:
hVEGF-A and -D (Quantikine®, R&D Systems) (I), hVEGF-C (Zymed) (I) and
osteoprotegerin (Quantikine, R&D Systems) (II). A sandwich ELISA was developed for
VEGF-B (I).
4.4 HISTOLOGICAL METHODS
For the histological analyses, mice were perfused via the left ventricle with phosphate-
buffered saline (PBS) and 10 % formalin (I) or 4 % paraformaldehyde (PFA, pH 7.4) (II-IV).
Tissue specimens were collected, post-fixed for 2-4 hours and processed for histology. Five
micrometer paraffin sections were used for histological analyses performed with general
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(hematoxylin-eosin) or special stainings (Masson’s Trichrome, modified Movat’s
pentachrome (Movat 1955), Alizarin Red S, Biotinylated or fluorescence-conjugated
Griffonia (Bandeiraea) Simplifonica Lectin I).
Immunohistochemical stainings were performed using the avidin-biotin-horseradish
peroxidase system (Vector Elite, Vector Laboratories) with 3-3’-diaminobenzidine (Zymed)
or alkaline phosphatase (Vector Laboratories) with fuchsin (Dako) as the chromogen. When
using mouse primary antibodies, the Dako ARKTM (Animal Research Kit, peroxidase, Dako)
was applied to minimize the reactivity of the secondary anti-mouse antibody with
endogenous  immunoglobulin  possibly  present  in  the  sample.  The  antibodies  used  in  the
different studies are presented in Table 7.
Table 7. Primary antibodies used in immunohistochemical stainings.
Antibody Specificity Species Dilution Distributor Study
mMQ Macrophages Rabbit anti-mouse pAb 1:5000-
1:6500
Accurate Chemical
& Scientific Corp.
I-II
CD-31 Endothelium Rat anti-mouse mAb 1:20-
1:50
BD Biosciences
Pharmingen
I, II,
IV
α-SMA Smooth muscle α–actin Mouse mAb 1:200 Sigma I-II
PCNA Proliferating cells Mouse mAb 1:500 NeoMarkers,
Lab Vision Ltd
II
Caspase-3 Apoptotic cells Rabbit anti-human pAb 1:250 Promega Corp. II, IV
OPN Osteopontin Goat anti-mouse pAb 1:500 R&D Systems II
RAGE Receptor for advanced
glycation end products
Goat anti-mouse pAb 1:50 R&D Systems II, IV
VEGF-A Vascular endothelial
growth factor A
Rabbit anti-mouse pAb 1:500 Serotec II
eNOS Endothelial nitric oxide
synthase
Rabbit and human pAb 1:150 BD Biosciences
Pharmingen
II
Nf-κB Nuclear factor kappa B
p65 subunit
Rabbit anti-human mAb 1:500 Nordic Biosite II
ICAM-1 Intercellular adhesion
molecule-1
Goat anti-mouse pAb 1:500 R&D Systems II
VCAM-1 Vascular adhesion
molecule-1
Rat anti-mouse mAb 1:100 Chemicon®
International
II
IL-6 Interleukin 6 Rat anti-mouse mAb 1:300 Lifespan
Biosciences
IV
Insulin Insulin, cytoplasm
of pancreatic β–cells
Guinea pig
anti-porcine pAb
1:100 DakoCytomation
Inc.
II
Glucagon Glugacon, cytoplasm
of pancreatic α–cells
Rabbit anti-human pAb 1:50 DakoCytomation
Inc.
II
NG2 Retinal pericytes Rabbit anti-rat pAb 1:200 Chemicon IV
Calbindin Amacrine cells in retina Rabbit anti-rat pAb 1:1000 SWANT IV
Calretinin Amacrine cells in retina Rabbit anti-human pAb 1:1000 SWANT IV
HSP-25 Heat shock protein
(25 kDa)
Rabbit anti-mouse pAb 1:500 Stressgen
Bioreagents
IV
HSP-60 Heat shock protein
(60 kDa)
Goat anti-human pAb 1:500 Stressgen
Bioreagents
IV
HSP-70 Heat shock protein
(70 kDa)
Rabbit anti-human pAb 1:200 Stressgen
Bioreagents
IV
Rhodopsin Photoreceptors (rod cells) Rabbit anti-human pAb 1:500 Chemicon IV
For ultrastructural analysis (III), the tissue samples were fixed overnight in 2.5 %
glutaraldehyde, treated with 1 % osmium tetroxide, dehydrated and embedded in LX-112
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resin and polymerized. 60-70 nm sections were contrasted with uranyl acetate and lead
citrate and examined by transmission electron microscopy (JEM 1200EX, JEOL Ltd. Japan).
4.5 EVALUATION OF ATHEROSCLEROSIS
In the en face analysis of atherosclerotic lesions, the aortas from heart to the iliac bifurcation
were collected after PBS and PFA perfusion and the adventitia was removed under a
dissection microscope (I-II). The aortas were opened longitudinally, pinned onto a black wax
dissection pan, imaged and the lesion area was quantified with an image analyzer
(MCID/M4, Imaging Research) (Leppänen et al. 1998).
The evaluation of lesion composition and the degree of arterial stenosis were performed
from serial paraffin cross-sections. Aortic lesions were studied in the level of sinuses to
assure identical anatomical locus for comparisons. Cross-sectional lesion area was calculated
as the percentage from the total aortic area limited by the tunica media (I-III). Plaque
calcification and cholesterol clefts were measured as a percentage from the respective plaque
area (II, III). In the assessment of coronary artery atherosclerosis, the arteries were followed
and lesion areas quantified in serial sections from the origin of the arteries towards the apex
of the heart (III). Analyses were performed in a blinded manner using AnalySIS software
(Soft Imaging System GmbH).
4.6 MEASUREMENT OF CARDIAC FUNCTION
Cardiac function (III) was assessed by performing transthoracic echocardiography with a
high-resolution imaging system for small animals (Vevo 770, VisualSonics Inc., Toronto,
ON, Canada) equipped with a high-frequency ultrasound probe (RMV-707B) (Huusko et al.
2010). The dimensions and wall thicknesses of the left ventricle (LV) in diastole and systole
were measured from parasternal short-axis M-mode images. Other parameters (ejection
fraction, fractional shortening, LV volume and LV mass) were calculated by the Vevo770
software. Ejection fraction was calculated with the Teicholz formula (Huusko et al. 2010).
The averaged values from 3 cardiac cycles were reported.
In the examination of myocardial viability, dobutamine stress echocardiography was
performed to evaluate cardiac functional reserve (III). The β-adrenoceptor agonist,
dobutamine, was injected intraperitoneally (1 µg/g) and echocardiography was performed at
baseline and after injection. Regional LV wall motion was evaluated before and after
dobutamine stress from electrocardiogram kilohertz-based visualization cine loops. A
12-segment model on two levels of short axis views (mid-ventricle and apical) comprising of
6 wall segments (anteroseptal, anterior, anterolateral, inferolateral, inferior, and inferoseptal)
was used. Wall motion was scored 1=normal, 2=hypokinetic, 3=akinetic and 4=dyskinetic,
and a score index was calculated as the sum of scores divided by the total number of
segments. In addition to the regional evaluation of the myocardium in dobutamine stress
echocardiography, LV wall  motion was also assessed in all  animals from the long-axis cine
view.
Myocardial perfusion (III) was measured with CadenceTM contrast  pulse sequence (CPS)
ultrasound by Acuson Sequoia C256 using 15L8 probe (Siemens Medical Solutions,
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Mountain View, CA, USA) and a second generation microbubble contrast agent (SonoVue,
Bracco Diagnostics Inc.,  Princeton,  NJ,  USA) administered as a 50 µl  bolus via the tail  vein
(Huusko et al. 2010). The quantification of CPS signal intensities was performed using
Datapro software (v2.13, Noesis SA, Courtaboeuf, France).
4.7 GENE EXPRESSION ANALYSES
Gene expression levels were examined in aortas (II) (Table 8). Tissue samples were cut from
both lesions and intact regions. Total RNA was extracted and reverse transcribed into
cDNA. The quantitative measurements of gene expression with real-time quantitative
RT-PCR were done using Assays-on-demand gene expression products (Applied
Biosystems) with the ABI PRISM 7700 Sequence Detection System (Applied Biosystems).
The expression levels were normalized to 18S ribosomal RNA (Applied Biosystems). All
experiments were done in duplicate.
Table 8. Aortic gene expression analyses.
Gene
Taqman® gene
expression assay
Biological function
Analyzed
tissues
OPN (Osteopontin) Mm00436767_m1
Regulation of vascular
calcification
Intact
vascular wall
and
atherosclerotic
lesion
ALP (Alkaline phosphatase) Mm00475831_m1
BMP-2 (Bone morphogenetic
protein 2)
Mm01340178_m1
Bax (Bcl-2–associated
X protein)
Mm00432050_m1 Apoptosis
IL-6 (Interleukin 6) Mm00446190_m1
InflammationMCP-1 (Monocyte
chemotactic protein 1)
Mm00441242_m1
CD36 (A class B scavenger
receptor)
Mm00432403_m1 Uptake of oxidized LDL
4.8 ASSESSMENT OF OCULAR PHENOTYPE
In addition to the histological analyses of the ocular structures, retinal vasculature was
studied in flat mounts with confocal microscopy (IV). Enucleated eyes were fixed in 4 %
PFA for 10 minutes, after which the retinas were dissected to flat mounts, further fixed for
1 hour and stained with fluorescence-conjugated lectin. Whole mount retinas were imaged
using a confocal microscope (Olympus IX70 inverted microscope). The in vivo evaluation of
the eyes (IV) included examination with a slit lamp, ophthalmoscopy and fundus
photography  performed  using  a  fundus  camera  (Nikon  D70s,  Nikon  Corp.,  Tokyo,  Japan)
after dilating pupils with tropicamide (5 mg/ml) and phenylephrine hydrochloride (100
mg/ml).
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4.9 STATISTICAL ANALYSES
In choosing the tests to evaluate statistical significance, analyses of distributions were
performed. Most data passed the Kolmogorov-Smirnov test for normality. However, the
power of the test to detect a Gaussian distribution is weak in a sample size less than a few
dozen. Since most biological data is generally close to the Gaussian distribution, and because
nonparametric tests lack power in small samples and can give misleading results from
Gaussion populations, the data scatter was visually checked to approximately follow the
Gaussian distribution, and parametric tests were chosen. Two-tailed Student’s t-test for
independent samples was used for comparing two groups, and paired t-test was applied to
comparing values before and after dobutamine challenge. For more groups, the one-way
analysis of variance (ANOVA) or ANOVA for repeated measures (for GTT and ITT) were
used with Bonferroni’s correction for multiple comparisons. The degree of association was
measured with two-tailed Pearson’s correlation coefficient (r) test. P values <0.05 were
considered significant. Numerical values for each measurement are shown as a mean ±
standard deviation (SD) or mean ± standard error of the mean (SEM) as stated. Statistical
analyses were performed using SPSS (SPSS 7.5, SPSS Inc.) (I) or GraphPad Prism 4.0
(GraphPad Software, USA) (II-IV).
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5 Results
5.1 EFFECTS OF VEGF GENE THERAPY ON ATHEROSCLEROSIS (I)
In the first study, the safety and effects of systemic adenoviral gene transfers with human
VEGF-A, -B, -C and -D on atherosclerosis were examined in hypercholesterolemic
LDLR-/-ApoB100/100 mice.  LacZ  was  used  as  a  control  gene.  In  addition,  a  systemic
administration of rhVEGF-A protein was included.
The plasma levels of gene expression products were detectable with ELISA until
4 (VEGF-B) to 6 weeks (VEGF-A, -C, and -D) after gene transfers, whereas the concentration
of rhVEGF-A was below the detection limits already 15 minutes after administration. As the
liver is the principal tissue of transduction and expression of systemically transferred genes
(Smith et al. 1993), increased hepatic neovascularization was seen after VEGF-A and VEGF-D
gene transfers. However, no changes were observed in the plasma levels of triglycerides or
total  cholesterol.  Human VEGF-A was found present also in aortic  tissue 5 days after gene
transfer, but no effects on lesion development, composition or neovascularization in the
adventitia were seen at the study end point 6 weeks after the gene transfer. Hence, it can be
concluded that although some animal studies have pointed to a pro-atherogenic role for
VEGF-A, a transient expression of VEGFs did not affect atherosclerosis in the
LDLR-/-ApoB100/100 mouse model.
5.2 MOUSE MODEL OF DIABETIC VASCULAR COMPLICATIONS (II-IV AND
UNPUBLISHED RESULTS)
5.2.1 Diabetic characteristics
To evaluate if the developed IGF-II/LDLR-/-ApoB100/100 model represented diabetic
characteristics, metabolic and morphological analyses were performed. The basic metabolic
parameters of the old animals used in the majority of studies (II-IV) are summarized in
Table 9. Overall, IGF-II/LDLR-/-ApoB100/100 mice presented elevated fasting plasma glucose
and insulin levels, whereas lipid values were not different from the hypercholesterolemic
LDLR-/-ApoB100/100 mice. In addition, the distribution of lipids in the different lipoprotein
fractions  was  similar  in  LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice (unpublished
results).
Table 9. Metabolic parameters from old (age 15-18 months) mice after 3 months of Western diet.
Analyzed parameters C57Bl/6J LDLR-/-ApoB100/100
IGF-II/
LDLR-/-ApoB100/100
Weight (g)
Females
Males
Glucose (mmol/l)
Triglycerides (mmol/l)
Cholesterol (mmol/l)
34.35 ± 6.55
44.77 ± 5.27
3.52 ± 0.75
0.99 ± 0.24
4.02 ± 1.36
31.01 ± 6.25
36.98 ± 6.35a
5.06 ± 1.86
1.50 ± 0.74a
24.19 ± 8.37c
33.58 ± 4.52
39.81 ± 4.35
7.94 ± 3.18b
1.38 ± 0.53
25.51 ± 6.37c
Glucose  and  lipid  values  are  plasma  concentrations  after  overnight  fasting.  Values  denote  mean ±
SD. aP<0.05 vs. C57Bl/6J. bP<0.001 vs. C57Bl/6J and LDLR-/-ApoB100/100. cP<0.001 vs. C57Bl/6J.
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Compared to the C57Bl/6J and LDLR-/-ApoB100/100 mice, IGF-II/LDLR-/-ApoB100/100 mice were
markedly glucose-intolerant (II-III): intraperitoneal glucose injection did not induce a
response  in  insulin  secretion  and  glucose  removal  from  blood  was  impaired  (5A).  In
addition, significant insulin insensitivity in response to an intraperitoneal administration of
insulin was seen in IGF-II/LDLR-/-ApoB100/100 mice (Figure 5B). These changes were present
independently of age and diet.
Figure 5. A, Glucose tolerance test in 18-month-old mice after 3 months of Western diet. B, Insulin
tolerance test in 6-month-old mice on normal diet. Values denote means ± SD. a P<0.05 in
C57Bl/6J vs. LDLR-/-ApoB100/100, b P<0.05 in C57Bl/6J vs. IGF-II/LDLR-/-ApoB100/100, c P<0.05 in
LDLR-/-ApoB100/100 vs. IGF-II/LDLR-/-ApoB100/100 .
In pancreas, immunohistochemical stainings with glucagon and insulin antibodies
revealed an abnormal islet architecture in the IGF-II/LDLR-/-ApoB100/100 mice: the islets were
irregular in shape and the distribution of α- and β-cells was disturbed (Figure 6)
(unpublished results). Thus, the morphological changes seen in the original IGF-II mouse
(Devedjian et al. 2000) had persisted. No such changes were observed in the
LDLR-/-ApoB100/100 controls.
Figure 6. Immunohistochemical stainings of
pancreatic sections in LDLR-/-ApoB100/100 (left
panel) and IGF-II/LDLR-/-ApoB100/100 mice
(right panel). In glucacon staining, a normal
distribution of α-cells in the periphery of
Langerhans islets was seen in LDLR-/-
ApoB100/100 mice (A), whereas in IGF-II/
LDLR-/-ApoB100/100 mice they are randomly
distributed (B). Compared to uniform islet
morphology in LDLR-/-ApoB100/100 mice (C),
irregularities in the shape and size of islets
were visible in the insulin-stained sections of
IGF-II/LDLR-/-ApoB100/100 mice (D). Original
magnifications x200 (A, B) and x100 (C, D).
Scale bars 50 µm (A, B), 100 µm (C, D).
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5.2.2 Macrovascular disease
To study if T2D would affect the macrovasculature, atherosclerotic lesions in young
(6 months) and old (15 and 18 months) mice on normal and Western diet were evaluated
and quantified en face in longitudinally opened aortas (II) and in serial cross-sections from
aortic sinus level (II-III). Combined results from studies II-III are presented in Figure 7.
There were no differences in overall lesion areas between IGF-II/LDLR-/-ApoB100/100 and
LDLR-/-ApoB100/100 mice: both models exhibited lesions covering of ~15 % of the total aortic
area and cholesterol elevation as induced by Western diet had no significant effect. On the
other hand, cross-sectional lesion areas were more responsive to aging and diet:  in
6-month-old mice, the Western diet increased the lesion area over 3-fold, and in old animals,
the increase was 1.5-fold. Despite the similar atheroma burden, plaques in diabetic
IGF-II/LDLR-/-ApoB100/100 mice were found to be significantly more calcified in comparison to
LDLR-/-ApoB100/100 mice  (Figure  7B,  E).  In  both  diabetic  and  non-diabetic  LDLR-/-ApoB100/100
mice, the extensive lesion formation at the aortic sinus was associated with a compensatory
enlargement of the vessel area, resulting in the preservation of the lumen area.
Figure 7. Quantification of atherosclerotic lesion areas (A) and plaque calcification (B) in old
LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice after Western diet. Representative aortic
cross-sections from C57Bl/6J (C), LDLR-/-ApoB100/100 (D) and IGF-II/LDLR-/-ApoB100/100 mice (E).
Calcification is indicated with arrowheads. Original magnifications x40, scale bars 200 µm.
When lesions were studied in order to discover possible mechanisms behind the
increased calcification, no quantifiable differences could be detected between the
IGF-II/LDLR-/-ApoB100/100 and LDLR-/-ApoB100/100 mice in immunohistochemical analyses (II).
Therefore gene expression studies were performed with quantitative real-time RT-PCR from
lesions and intact aorta (II). In lesions, the gene expression levels were comparatively similar
in both groups. Interestingly, in healthy aortas, the basal expression levels of genes related
to calcification (OPN, ALP-2, BMP-2), inflammation (MCP-1) and oxidized LDL uptake
(CD36) were higher in IGF-II/LDLR-/-ApoB100/100 mice, indicative of a more inflammatory
vascular profile typical of diabetes.
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In the evaluation of coronary atherosclerosis, severely stenotic coronary arteries were
seen in both LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice (Figure 8) (III). Stenosis was
most prominent in the left coronary artery in which the lumen area was significantly
narrowed in all LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice (average luminal
stenosis of ~80 %) despite outward remodeling. The right coronary and septal arteries were
stenosed in fewer animals, although also there the narrowing was as severe as in the left
coronary when it was present. Despite severe atherosclerosis in the proximal coronary
arteries, no lesions were detected in the distal parts. In C57Bl/6J mice, no lesion formation
was observed in any part of the coronary tree.
Figure 8. Assessment  of  coronary  artery  atherosclerosis.  A)  Stenoses  of  coronary  arteries  with
atherosclerotic lesions in old C57Bl/6J, LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice after
Western diet. Representative cross-sections from left coronary arteries in C57Bl/6J (B),
LDLR-/-ApoB100/100 (C) and IGF-II/LDLR-/-ApoB100/100 mice (D). Original magnifications x200, scale
bars 50 µm.
In order to determine whether T2D would affect cardiac performance, the function of the
LV  in  old  animals  was  examined  (Figure  9)  (III).  Compared  to  C57Bl/6J  mice,  which
represented a normal global heart function assessed by echocardiography, severe contractile
dysfunction was evident in both LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice
(LV ejection fraction 73.0 ± 9.5 % vs. 44.9 ± 14.7 % and   48.2 ± 11.0 %, respectively). In
addition, these groups presented LV dilatation with an increased size and decreased
thickness of the LV walls. The visual evaluation of 2-dimensional cine loops revealed also
impaired LV wall motion and even akinesia in the anteroapical areas. Animals with the most
severe dysfunction exhibited high aortic cross-sectional lesion areas (> 70 %), calcified
plaques (4 - 12 % of the plaque area), severe coronary artery stenoses (> 93 % occlusion in left
coronary  artery)  and  LV  ejection  fraction  of  22  -  47  %. β-adrenergic stimulation with
dobutamine induced chronotropic and inotropic responses in all strains, but in relation to
baseline  values,  the  response  was  diminished  in  both  LDLR-/-ApoB100/100 and
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IGF-II/LDLR-/-ApoB100/100 mice. However, despite the poor regional wall motion at baseline
especially in the LDLR-/-ApoB100/100 mice, all of the animals showed improvements in wall
motion in response to the β-adrenergic stimulation, evidence of a viable myocardium.
Figure 9. Left ventricular parameters assessed by echocardiography in old mice after Western diet
are  indicative  of  dysfunction  with  reduced  pumping  efficiency  and  dilatation.  A)  Reduced  LV
ejection fraction in LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice depicting a decreased
amount  of  blood  pumped  out  of  the  LV  in  systole.  B)  Increased  internal  LV  diameter  in
LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice in both diastole and systole. Thinning of the
anterior  (C)  and  posterior  (D)  LV  walls  in  LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice.
Values denote mean ± SD.  * P<0.05  vs.  C57Bl/6J.  AW,  anterior  wall;  EF,  ejection  fraction;  ID,
internal diameter; LV, left ventricle; PW, posterior wall.
LV anterior wall perfusion was measured with contrast-enhanced ultrasound and a trend
towards reduced perfusion was seen in LDLR-/-ApoB100/100 and IGF-II/LDLR-/-ApoB100/100 mice.
In the histological investigation of the myocardium, no scarring indicative of myocardial
infarction was detected. Nevertheless, electron microscopy revealed an ischemic yet viable
myocardium and changes reflecting myocardial hibernation in LDLR-/-ApoB100/100 and
IGF-II/LDLR-/-ApoB100/100 mice.
5.2.3 Ocular phenotype
As retinopathy is the most common microvascular complication of diabetes, the ocular
phenotype of the IGF-II/LDLR-/-ApoB100/100 mice was investigated (IV). No signs of
neovascularization or microvascular damage were observed in fundus photographs, retinal
whole mounts or histological analysis. However, the retinal morphology of
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IGF-II/LDLR-/-ApoB100/100 mice showed abundant alterations (Figure 9) not present in
C57Bl/6J or LDLR-/-ApoB100/100 mice. In addition, atrophy of photoreceptors was observed in
IGF-II/LDLR-/-ApoB100/100 mice, which was supported by an increased expression of caspase-3,
and reduced positivity in rhodopsin staining. These findings were not dependent on aging
or diet, but were present both in young (3 months) and old (15 months) animals fed either a
normal or Western diet.
Figure 10. Hematoxylin-eosin stained sections showing retinal changes found in
IGF-II/LDLR-/-ApoB100/100 mice. A) Lack of  organized structure and displaced cells  in the retina of
IGF-II/LDLR-/-ApoB100/100 mice fed with normal diet. B) Photoreceptor atrophy and thinning of the
outer nuclear layer (arrows) with large acellular areas (arrowheads) in outer nuclear layer.
C) LDLR-/-ApoB100/100 mice demonstrated normal retinal morphology. Original magnification x400,
scale bar 25 μm. GCL, ganglion cell layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL,
outer plexiform layer; ONL, outer nuclear layer; IS, inner segment; OS, outer segment.
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6 Discussion
6.1 VEGF GENE THERAPY AND ATHEROSCLEROSIS
As one of the cytokines shown to enhance angiogenesis, VEGF-A is considered as a potent
therapeutic agent to stimulate blood vessel formation in myocardial and limb ischemia
(Zachary, Morgan 2011). However, neovascularization is also associated with the growth
and progression of atherosclerotic lesions (Moreno et al. 2006). Although to date,
placebo-controlled clinical trials have not shown any indication that VEGF-A would
promote or accelerate atherosclerosis and its clinical outcomes (Hedman et al. 2009, Muona et
al. 2011), concerns about the safety of VEGF-A gene therapy and the role of VEGF-A in
atherogenesis have been raised based on some animal studies. Celletti et al. (2001a, 2001b)
reported increased atherosclerosis in ApoE-/-ApoB100/100 mice and cholesterol-fed rabbits after
single intraperitoneal and intramuscular injections of low-dose (2 µg/kg) rhVEGF-A protein.
Furthermore, a reduction in the lesion amount has been achieved in ApoE-/- mice by using
endothelial cell -specific angiogenesis inhibitors (Moulton et al. 1999). Since clinical studies
with products based on VEGF-A and other angiogenic factors for the treatment of tissue
ischemia are currently ongoing, these observations from animal studies have raised concerns
about the possibility of atherosclerosis progression. We addressed this question by studying
the effects of systemic administration of human VEGF-A protein and adenoviral gene
transfers with human VEGF-A, -B, -C and -D on atherosclerosis in hyperlipidemic
LDLR-/-ApoB100/100 mice.
In the present study, the transient expression of VEGFs did not increase aortic
atherosclerosis in LDLR-/-ApoB100/100 mice despite the fact that human VEGF-A was detected
as being present in aortas with over 7-fold concentration compared to the endogenous
mouse VEGF-A. The plasma levels of expressed gene products peaked around day 4 and
diminished during the next two weeks, which is a typical expression pattern for adenovirus
(Hiltunen et al. 2000). On the other hand, when rhVEGF-A protein was administered i.v. in
the same amount as i.p. in the study of Celletti et al. (2001b), it was undetectable from
plasma already after 15 minutes. This is in line with human pharmacokinetic studies
showing a rapid clearance from the circulation within hours from intravenous
administration. Indeed, in the “VEGF in Ischemia for Vascular Angiogenesis” clinical trial,
an i.v. dosing of rhVEGF-A (12 µg/kg) was sufficient to saturate high-affinity receptors for
7 hours and elicit acute effects, such as transient hypotension caused by the activation of
endothelial NO synthase and subsequent NO release (Eppler et al. 2002). However, this
duration of saturation is probably not enough to stimulate any longer-term effects, like
angiogenesis, and thus the biological efficacy of a single low-dose bolus of VEGF-A protein
used in previous animal studies remains controversial. In fact, it has been noted that a
duration of >2 weeks of high VEGF-A expression is needed to induce durable functional
vessels in mice with reversible VEGF-A induction (Dor et al. 2002).
Although plaque neovascularization is a prominent feature of human atherosclerosis, its
significance in mice is less certain. Since blood nutrients are capable of diffusing a distance
of ~100 µm (Krogh 1919), only relatively large plaques exceed this limit in mice. Therefore it
is logical that the incidence of intimal vessels in mice is actually quite low - e.g. only 15 of
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114 advanced lesions in ApoE-/- mice were reported to contain intimal neovascularization
(Moulton et al. 1999). A role for adventitia as a source of plaque microvessels has also been
postulated (Moreno et al. 2006) and the inhibition of adventitial angiogenesis has been
shown to reduce lesion area in mice (Drinane et al. 2009, Moulton et al. 2003) and pigs (Gössl
et al. 2009). On the other hand, an antibody-blockade of the VEGF receptor 2, which
mediates the angiogenic effects of VEGF-A, did not affect atherosclerosis in ApoE-/- mice
(Luttun et al. 2002), suggesting that the overall role of angiogenesis is not superior in the
complex process of atherogenesis. Moreover, these studies test the effects of angiogenesis
inhibition, not the hypothesis that the administration of proangiogenic factors would
enhance either adventitial neovascularization or atherosclerosis. In the present study, no
changes were observed in the adventitial angiogenesis of intact or plaque-related aortic
areas after VEGF-A gene transfers. These facts raise the question if the effects of VEGF-A
seen on atherosclerosis in some studies are being mediated through angiogenesis or by some
other mechanisms. The conflicting results obtained from different mouse models also imply
that some model-dependent factors, such as differences in lipoprotein metabolism, may be
underlying  these  discrepancies.  Further  studies  comparing  different  models  might  help  to
elucidate this matter.
Even though in general the extrapolation from animals to humans is not straightforward,
animal model selection can affect the results greatly and is of major importance in the
preclinical research of potential human therapies. To date, the greatest problem in clinical
trials of therapeutic angiogenesis is the lack of efficacy - promising results achieved in
preclinical studies have not been translated into human trials (Zachary, Morgan 2011).
A number of factors can contribute to this discrepancy. Firstly, in animal experiments, the
study population is very homogenous with identical genetic background, living conditions
and disease phenotype. In clinical trials, on the other hand, the patient population is very
heterogenous with different clinical pictures and comorbidities, and responses to treatment
vary. Additionally to high individual variation in revascularization potential, concomitant
medications can contribute to the effectiveness of angiogenic therapy. For example, non-
steroidal anti-inflammatory drugs possess some inhibitory effect on angiogenesis
(Tarnawski, Jones 2003), and statins have been suggested to promote dose-dependently
either pro- or antiangiogenic effects (Weis et al. 2002, Urbich et al. 2002, Boodhwani et al.
2006). Secondly, animal models might lack fidelity to the human clinical phenotype. It has
been suggested that molecular, cellular and microvascular environments contribute to the
efficacy of angiogenic gene therapy products. For example, NO has a crucial role in the
angiogenic process and partly mediates the effects of VEGF-A. Decreased NO availability, a
typical feature of endothelial dysfunction caused by various cardiovascular risk factors, can
impair both endogenous and exogenous angiogenic responses and might thus attenuate also
the effects of angiogenic therapy (Boodhwani, Sellke 2009). It is obvious that studies
performed in healthy animals do not capture this situation. Since aging is also usually
associated with more advanced disease and poorer recovery both in humans and animals
(Faber et al. 2011), preclinical studies using young animals might provide an overoptimistic
picture of the therapeutic efficacy. At present, the clinical trials have mostly been performed
in no-option patients with end-stage diseases, in which measurable improvements might in
general be hard to accomplish (Gupta, Tongers & Losordo 2009). Nevertheless, even if at
some point clinical trials could enroll patients at an earlier disease stage, young and healthy
animals are unlikely going to be relevant models for even their condition. Thirdly, in
addition to species-, age- and heath-related issues, the differences can also be a consequence
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of vector biology, leading to false conclusions about the efficacy of the therapeutic agent
itself. For example, the transfection efficacy of adenovirus is in general markedly less in
humans than in mice (Ylä-Herttuala, Alitalo 2003), and even in animals, it declines with
aging (Communal et al. 2003).
6.2 MOUSE MODEL OF DIABETIC CARDIOVASCULAR COMPLICATIONS
T2D is globally approaching epidemic proportions and concurrently increases the number of
CVD patients with a complex clinical picture. Better animal models are urgently needed for
the study of disease mechanisms, development of new therapeutic approaches and for the
improvement of the current treatments. The present study aimed to develop a new mouse
model mimicking the cardiovascular complications encountered in T2D and to evaluate its
applicability by performing a thorough phenotypic characterization.
Cross-breeding of the IGF-II transgenic mice with hyperlipidemic LDLR-/-ApoB100/100 mice
resulted in a model exhibiting hyperglycemia, IR and after high-fat diet feeding also
hyperinsulinemia. As an advantage, compared to most other models attempting to combine
diabetes and hyperlipidemia, there were no diabetes-induced changes in the plasma lipid
levels or lipoprotein profiles. Therefore the IGF-II/LDLR-/-ApoB100/100 mice offer the
possibility to study the cardiovascular effects of diabetes in parallel to non-diabetic controls
with identical lipid levels. There are few models which permit this comparison. The role of
STZ-induced hyperglycemia can be assessed in ApoE-/- mice with a defective antioxidant
defense (Lewis et al. 2007), and in mice overexpressing human AR in LDLR+/- or ApoE-/-
backgrounds (Vikramadithyan et al. 2005, Vedantham et al. 2011). With diet-induced obesity
and diabetes, only one study in ApoE-/- mice has reported increased lesion formation without
concurrent changes in plasma lipids (King et al. 2010). From genetic models, the effects of IR
without any hyperglycemia can be studied in ApoE-/- mice with IRS2 deficiency (Clough et al.
2005, Baumgartl et al. 2006). Although the problem of increased lipid levels is avoided in
these models, a general downside is that models based on the ApoE-/- background are very
different from humans in relation to lipoprotein metabolism and thus are not the optimal
model for atherosclerosis studies.
T2D did not increase either the total aortic lesion area or the cross-sectional lesion
thickness at the aortic sinus level in LDLR-/-ApoB100/100 mice. This is likely attributable to the
high cholesterol level of the LDLR-/-ApoB100/100 background, and its widely recognized impact
on mouse atherogenesis. However, in aged diabetic IGF-II/LDLR-/-ApoB100/100 mice, the lesion
morphology was altered with an increased prevalence of calcified lesions, indicative of
accelerated lesion progression. Atherosclerotic lesion calcification is a common phenomenon
in advanced atherosclerotic lesions in humans (Stary et al. 1995) and is more prevalent in
diabetic patients (Mielke, Shields & Broemeling 2001), probably reflecting the generally
greater atheroma burden. It occurs also in hypercholesterolemic mouse models (Roselaar,
Kakkanathu & Daugherty 1996), correlating with the severity of hyperlipidemia (Roselaar,
Kakkanathu & Daugherty 1996, Qiao et al. 1994). In general, atherosclerotic calcification
arises from dead and dying vascular SMCs with a contribution of following osteogenic and
chondrogenic processes (Shao, Cai & Towler 2006). The procalcific process is initiated by
stimuli related to inflammation and oxidative stress (Demer, Tintut 2008), which are
typically pronounced in diabetes. However, data from mouse models of diabetic
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atherosclerosis is limited - an up-regulation of osteogenic genes has been found in aortas of
LDLR+/- mice with a diet-induced diabetes (Towler et al. 1998), and ApoE-/- mice with
STZ-induced hyperglycemia display increased lesion calcification (Tse et al. 1999). In our
study, the aortic vascular wall of IGF-II/LDLR-/-ApoB100/100 mice demonstrated a more
inflammatory profile and an increased expression of calcification-related genes as compared
to non-diabetic LDLR-/-ApoB100/100 mice. This finding is in line with studies reporting an
increased expression of the BMP-mediated signaling system in different diabetic mouse
model (Nett et al. 2006, Boström et al. 2011, Zervou et al. 2010). In addition, the fact that
calcification was most profound in old animals is concordant with clinical studies, where
especially age and the duration of diabetes have remained as independent risk factors for
coronary artery calcification in patients with type 2 diabetes after multivariate analysis
(Wagenknecht et al. 2001, Godsland et al. 2006). In contrast to humans, where plaque
neovascularization is closely related to accelerated plaque progression in diabetic patients
(Purushothaman et al. 2011), no differences were observed here in angiogenesis. This might
be a consequence of the fact that lesion size per se was not increased, and that generally the
significance of plaque angiogenesis in mice is not necessarily similar to humans.
Instead of an actual numeral lack of models with diabetic atherosclerosis, there is a lack of
well characterized models. Although it is well-known that T2D significantly increases the
risk of coronary events in humans, the main emphasis in mice has been on the assessment of
aortic atherosclerosis and, somewhat surprisingly, data about the coronary artery status is
missing and there is very little knowledge about their cardiac phenotype. In fact, the cardiac
function has thus far been examined only in LDLR-/-ob/ob mice, where increased ventricular
stiffness was found (Verreth et al. 2004, Verreth et al. 2006, Van den Bergh et al. 2008, Van
den Bergh et al. 2009). In the present study, CAD and cardiac function were characterized in
diabetic and non-diabetic LDLR-/-ApoB100/100 mice. Irrespective of the more calcified aortic
lesions, diabetes did not lead to worsened CAD: the proximal coronary arteries were found
to be significantly stenosed in both models, despite an extensive positive remodeling of the
vessels. Consequently, although aortic calcification could increase cardiac work by reducing
aortic compliance, also the cardiac outcome was similarly impaired in both models and
although regional akinesia was seen, no clear signs of myocardial infarction were detected.
These results are in line with previous studies from different atherosclerosis models.
Proximal lesions without signs of an infracted myocardium have been found in LDLR-/-
ApoB100/100 mice also previously (Saraste et al. 2008) and in some studies using ApoE-/- mice
(Coleman et al. 2006, Dworschak et al. 2005, Kuhlencordt et al. 2001), although in ApoE-/- mice
a complete spectrum ranging from totally clean coronary arteries (Coleman et al. 2006) to
coronary artery occlusion with myocardial infarction has also been reported (Nakashima et
al. 1994, Chase et al. 2007). However, there is no previous data in the context of diabetes.
Therefore a thorough characterization of the vascular and cardiac phenotype of a mouse
model combining common metabolic disorders, CAD and chronic myocardial
hypoperfusion in the present study is of value to future experimental research.
In an attempt to study the possible manifestation of diabetic microvascular complications,
the ocular phenotype of the IGF-II/LDLR-/-ApoB100/100 mice was characterized. No vascular
alterations indicative of diabetic retinopathy were observed in the IGF-II/LDLR-/-ApoB100/100
mice. In fact, features of advanced stages of diabetic retinopathy, such as retinal
neovascularization, are generally missing in all diabetic mouse models. Only the recently
developed Akimba mouse has demonstrated the characteristics of proliferative diabetic
retinopathy, although even in that model the neovascular changes do not arise from
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hyperglycemia, but from a transgenic up-regulation of VEGF in the photoreceptors (Rakoczy
et al. 2010). Instead of diabetic retinopathy, the photoreceptor atrophy found in
IGF-II/LDLR-/-ApoB100/100 mice points to some form of retinal degeneration. Dysfunction and
a loss of photoreceptors are the major underlying causes of blindness in industrialized
countries, and typically manifest in age-related macular degeneration and in complex
hereditary disorders, such as retinitis pigmentosa (Wright et al. 2010). It has been observed
both in humans and mice that photoreceptor degeneration offers protection from the
reactive retinal neovascularization typically encountered in diabetic retinopathy (Arden
2001, Lahdenranta et al. 2001). Hence it is possible that the absence of diabetic vascular
changes is a consequence of photoreceptor atrophy also in IGF-II/LDLR-/-ApoB100/100 mice.
Nevertheless, the cause of the degenerative changes is unclear. Further studies assessing the
ocular ultrastructure and retinal function with electroretinography could provide more
information about the observed changes.
6.3 LIMITATIONS OF MOUSE MODELS IN ATHEROSCLEROSIS RESEARCH
Despite the facts that there are many similarities in the atherosclerotic process between
genetically engineered mouse models and humans, and that mice are very common model
animals for studying the cellular and molecular mechanisms of atherosclerosis, limitations
do exist. Differences in vessel architecture impact also on lesion structures: human lesions
are often more fibrous due to the intimal SMCs and connective tissue, whereas in mice, the
intima is very thin, consisting mainly of only endothelium. Furthermore, early stage lesions,
such as fatty streaks and intermediate lesions without a necrotic core, do not have clinical
consequences  in  humans  and  can  actually  regress  to  normal  instead  of  progressing  into
more mature plaques (Stary 2000). These foam cell lesions have even been suggested to be
called as “non-atherosclerotic intimal lesions” (Virmani et al. 2000). Yet in many studies
using mice it is the early lesions that prevail. Since the main goal of experimental studies is
to investigate clinically significant atherosclerosis, the term atherosclerosis is used somewhat
vaguely when it comes to mouse studies and should be used only when some hallmarks of
mature or progressive lesions are present (Getz 2000). Due to the short duration of most
mouse studies, it might also be that there is simply a general failure to observe clinically
significant lesions. Therefore the characterization of older animals is of value and was
performed in the present study. In fact, it was found that the effects of diabetes on
atherosclerosis did not manifest themselves until later i.e. in older animals with a more
advanced disease state.
Having said that the goal is to model clinically significant atherosclerosis, it is also
somewhat uncertain if human-like plaque rupture and superimposed thrombosis take place
in mice at all (Schwartz et al. 2007). Ruptured plaques have been reported in the
brachiocephalic artery of fat-fed ApoE-/- mice (Jackson et al. 2007), but they do not fulfil all
the criteria of the human situation. Although this is a shortcoming, it does not necessarily
devalue the usefulness of the mouse as a model animal, since it is possible that the process in
mice is simply markedly different in terms of histopathology or physiology (Jackson 2007).
In fact, major variation appears in coagulation and thrombosis in different mouse strains
(with C57Bl/6, the most widely used background strain in atherosclerosis studies, being
rather resistant to thrombosis) (Peters et al. 2002, Hoover-Plow et al. 2006)  as  well  as  in
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comparison to humans (Magallon et al. 2011).  In  addition,  diabetic  db/db  and  ob/ob  mice
actually demonstrate reduced blood coagulation and aggregation compared to their
respective genetic controls, and thus do not reproduce the hypercoagulable state seen in
human patients with T2D (Henry et al. 2008). The fact that mice are seemingly protected
against the clinical consequences of thrombosis, such as ischemic heart disease, might also
be attributable to the different patterns of lesion distribution also observed in the present
study - e.g. in their coronary arteries, mice exhibit mainly only retrovalvular lesions and the
sites usually diseased in humans (the first segment and branches) are free of atherosclerosis
(Hu et al. 2005). However, strong data supporting a generally similar pathophysiology of
atherosclerosis comes from the genetic analyses, where a number of corresponding
quantitative trait loci have been discovered in both mice and men (Wang et al. 2005).
In general, the usage and selection of an animal model is always more or less of a
compromise. Although non-human primates would be excellent model animals in CVD
research, they are hardly the ideal choice for many reasons related to handling, expences
and ethical concerns. Pigs share great anatomical, histological and mechanistical similarities
with human atherosclerosis and strains with different stages of metabolic disorders are
available, although overt diabetes has to be induced chemically (Bellinger, Merricks &
Nichols  2006).  Rabbits  differ  more  from  humans  in  relation  to  lipid  metabolism  and
atherosclerotic lesions, although a spontaneously hyperlipidemic strain and some transgenic
rabbits are available. However, also in rabbits, only chemically induced diabetes can be
studied. (Singh et al. 2009). The rat has the advantage of a sequenced genome (Rat Genome
Sequencing Project Consortium 2004), and the number of genetically modified strains is
likely to increase. However, they offer little benefit over the mouse, especially since surgical
and imaging techniques for small animals are constantly improving.
6.4 FUTURE DIRECTIONS IN MOUSE MODEL DEVELOPMENT
There is no perfect model available for diabetic cardiovascular complications, but many
options for modeling different aspects of these complications. One can even speculate
whether developing such a model is possible. However, it is possible to improve the present
mouse models of atherosclerosis by further genetic optimization of lipid metabolism. It
would be desirable to achieve conditions, where the use of very high-fat diets could be
avoided and advanced atherosclerotic lesions would be obtained with physiological and
clinically relevant plasma lipid levels. Although the LDLR-/-ApoB100/100 mice represent the
most human-like lipoprotein profile so far, the fact that mice in general do not express CETP
significantly contributes to their high HDL levels and subsequent resistance to
atherosclerosis. Therefore a transgenic induction of CETP expression could be used for
lowering their naturally high HDL levels. Since the plasma total cholesterol concentration of
LDLR-/-ApoB100/100 mice is ~8 mmol/l and advanced atherosclerotic lesions are formed also on
a  normal  diet,  the  expression  of  CETP could  be  used  to  fine-tune  their  lipid  profile  and to
achieve a very satisfactory mouse model of human atheroslcerosis.
The situation with diabetes-induction and with modeling the subsequent increase in
atherosclerosis is more challenging. Ultimately, if the less frequent monogenic forms are
omitted, T2D and related metabolic disorders are complex and multifactorial, and thus their
simulation in animal models is anything but simple. The possible mechanistical interspecies
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differences underlying the lack of accelerated atherogenesis typically seen in diabetic human
patients complicate the task further. The development of new animal models is slow,
unpredictable and requires considerable resources. Thus a profound characterization
establishing the relevance of the models for the human pathophysiology is a necessity.
Therefore, as animal models represent an indispensable tool for a wide area of preclinical
research, their development should also be supported by minimizing the publication bias in
favor of experiments or models showing only positive results, so that all information would
be available and lessons learned in these studies would not need to be duplicated.
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7 Conclusions and future perspectives
The following conclusions can be drawn based on this thesis.
I Adenoviral gene transfers of human VEGF-A, -B, -C or -D do not increase
atherosclerosis in hypercholesterolemic LDLR-/-ApoB100/100 mice. This supports the results
from previous clinical trials indicating the safety of VEGF gene therapy.
II IGF-II/LDLR-/-ApoB100/100 mouse model represents T2D with insulin resistance,
hyperglycemia and mild hyperinsulinemia, and more advanced aortic atherosclerosis
with increased lesion calcification. This is one of the few models where the effects of
diabetes can be studied uncomplicated by concomitant lipid changes.
III Hypercholesterolemic LDLR-/-ApoB100/100 mice with or without diabetes develop
significant CAD and severe left ventricular dysfunction with regional akinesia but
without infarction, and possess an ischemic but viable myocardium. Although cardiac
function is not worsened by diabetes, the combination of common metabolic disorders,
CAD and chronic myocardial hypoperfusion will be useful for future studies.
IV The ocular phenotype of IGF-II/LDLR-/-ApoB100/100 mice reveals alterations in retinal
morphology with photoreceptor atrophy. No vascular alterations indicative of diabetic
retinopathy were observed. Hence the model might be useful for studying changes
related to early or pre-diabetes, and disorders involving retinal degeneration.
The results obtained in this thesis raise the question about the etiology of VEGF-induced
atherogenesis observed in some studies using different mouse models. Further studies
investigating the underlying mechanisms and possible model-dependent factors would
elucidate this clinically highly relevant issue. Since diabetic patients experience poor
recovery from myocardial ischemia and suffer from more severe peripheral arterial disease,
it would be important to evaluate if the IGF-II/LDLR-/-ApoB100/100 mouse reproduces these
features and the impairments in angiogenic potential. The developed model provides a
valuable tool for preclinical research and the development of new therapeutic approaches
for T2D related cardiovascular complications.
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Animal models are essential tools 
in the preclinical research of 
complex metabolic disorders. In 
this thesis, a new mouse model 
representing type 2 diabetes and 
associated vascular complications 
was developed and characterized. 
Furthermore, insight into the safety 
of cardiovascular gene therapy 
is given by in vivo evaluation of 
proangiogenic gene transfers in 
relation to atherosclerosis.
 
